[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 265
1. Qian SX, Li JY, Wu HX, Zhang R, Hong M, Xu W, Qiu HX: [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):464-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
  • The objective of this study was to evaluate the efficacy and toxicity of the fludarabine combination with high-dose cytarabine (Ara C), idarubicin and granulocyte colony-stimulating factor (G-CSF) (IDA-FLAG regimen) in treatment of refractory/relapsed acute leukemia (AL) patients.
  • 4 patients were male aged from 32 to 44 years, consisted of 3 cases of acute myeloid leukaemia (AML) and 1 cases of acute lymphocytic leukaemia (ALL).
  • The results showed that after one course of induction therapy, 4 patients all achieved complete remission (CR), in which 2 patients were in continuous CR after a follow-up of 3 and 4 months; 1 patient relapsed after 10 months and another one patient died of thrombotic thrombocytopenic purpura at 4 months after allogeneic peripheral blood stem cell transplantation.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379589.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


2. Willemze AJ, Geskus RB, Noordijk EM, Kal HB, Egeler RM, Vossen JM: HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant; 2007 Aug;40(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI.
  • To examine relapse, survival and transplant-related complications in relationship to disease- and pre-treatment-related characteristics, we evaluated 132 children, who consecutively received an allogeneic HLA-identical SCT for acute leukaemia in our centre: ALL in first remission (n=24), ALL in second remission (n=53) and AML in first remission (n=55).
  • The incidence of acute GVHD was 17%; 6% was grades II-IV.
  • AML patients with acute GVHD got no relapse (P=0.02); this was not the case in ALL patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572715.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A: Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. Eur J Haematol; 2008 Feb;80(2):107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: An aberrant pattern of expression of L-selectin and intercellular adhesion molecule 1 (ICAM1) may characterise CD34+ blast cells in myelodysplastic syndromes (MDS) and secondary acute myeloid leukaemia (sAML).
  • Furthermore, in two patients a decrease of the ratio was observed when overt leukaemic transformation occurred; conversely, restoration of a normal ratio was observed in two patients after a chemotherapy-induced remission.
  • (ii) the ratio of their expression has a prognostic role; and (iii) a ratio <1 significantly predicts progression to overt leukaemia in MDS patients.
  • [MeSH-major] Gene Expression Regulation. Intercellular Adhesion Molecule-1 / biosynthesis. L-Selectin / biosynthesis. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Bone Marrow / metabolism. Disease Progression. Female. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / metabolism. Male. Middle Aged. Prognosis. Time Factors


Advertisement
4. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M, Nakamura S, Tomita A, Abe A, Kiyoi H, Kinoshita T, Naoe T: Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol; 2008 Feb;140(4):394-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome.
  • Wnt signaling activates the canonical pathway and induces the accumulation of non-phosphorylated beta-catenin (NPBC) in the nucleus.
  • This study examined the expression of nuclear NPBC in bone marrow specimens from 54 and 44 patients with de novo acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), respectively.
  • On immunohistochemistry with an anti-NPBC antibody, the nuclei were positively stained in 22 and 18 of AML and MDS specimens, respectively.
  • Staining of nuclear NPBC was associated with AML subtypes (M6 and M7), low complete remission (CR) rate, and poor prognosis.
  • These findings suggest that in situ detection of nuclear NPBC by immunohistochemistry could provide new insights into the pathogenesis and prognosis of AML and MDS.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. beta Catenin / metabolism


5. Brethon B, Yakouben K, Oudot C, Boutard P, Bruno B, Jérome C, Nelken B, de Lumley L, Bertrand Y, Dalle JH, Chevret S, Leblanc T, Baruchel A: Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol; 2008 Nov;143(4):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
  • Gemtuzumab ozogamicin (GO) monotherapy is reported to yield a 20-30% response rate in advanced acute myeloid leukaemia (AML).
  • This study examined the efficacy and tolerability of GO combined with cytarabine (GOCYT) in children with refractory/relapsed CD33(+) AML.
  • At the outset of GOCYT, two patients were refractory; eight patients were in refractory first relapse; six patients had relapsed after stem cell transplantation (SCT); and one patient [del(5q) therapy-related AML (t-AML)] had not yet been treated.
  • Ten responses were obtained after GOCYT induction, including complete remission (CR) or CR without complete recovery of platelets (CRp) in six patients (35%).
  • GOCYT combination therapy yielded a high response rate (53%) and showed acceptable toxicity in heavily pretreated children with refractory/relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Aug;146(3):342-4 [19545292.001]
  • (PMID = 18759760.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab; 04079A1RDZ / Cytarabine
  •  go-up   go-down


6. Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ, International BFM Study Group on Paediatric AML: Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol; 2010 Mar;148(5):768-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.
  • The prognosis of children with relapsed/refractory acute myeloid leukaemia (AML) is poor, and new therapies are needed.
  • Thirty children who were refractory to re-induction at first relapse or suffered from second relapse of AML received a total of 64 infusions of GO.
  • The response rate [complete remission (CR) and CR with insufficient platelet recovery] was 37%.
  • This study showed a favourable safety/efficacy profile of single-agent GO in children with refractory first or second relapse of AML.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995399.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


7. Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA: Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother; 2006 Jan;55(1):68-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a whole cell vaccine for acute myeloid leukaemia.
  • We describe the modification of tumour cells to enhance their capacity to act as antigen presenting cells with particular focus on the use of costimulatory molecules to do so.
  • We have been involved in the genetic modification of tumour cells to prepare a whole cell vaccine for nearly a decade and we have a particular interest in acute myeloid leukaemia (AML).
  • AML is an aggressive and difficult to treat disease, especially, for patients for whom haematopoietic stem cell (HSC) transplant is not an option.
  • AML patients who have a suitable donor and meet HSC transplant fitness requirements, have a 5-year survival of 50%; however, for patients with no suitable donor or for who age is a factor, the prognosis is much worse.
  • It would be hoped that immunotherapy would be used to clear residual tumour cells in these patients in the first remission following standard chemotherapy treatments and this will extend the remission and reduce the risk of a second relapse associated with disease progression and poor mortality rates.
  • In this symposia report, we will focus on whole cell vaccines as an immunotherapeutic option with particular reference to their use in the treatment of AML.
  • We will aim to provide a brief overview of the latest data from our group and considerations for the use of this treatment modality in clinical trials for AML.
  • [MeSH-major] Cancer Vaccines / immunology. Immunotherapy / methods. Leukemia, Myeloid / immunology. Leukemia, Myeloid / therapy
  • [MeSH-minor] 4-1BB Ligand. Acute Disease. Animals. Antigen-Presenting Cells. Autoimmunity. Disease Models, Animal. Humans. Mice. Prognosis. Tumor Necrosis Factors / immunology. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891884.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Cancer Vaccines; 0 / TNFSF9 protein, human; 0 / Tnfsf9 protein, mouse; 0 / Tumor Necrosis Factors
  • [Number-of-references] 65
  •  go-up   go-down


8. Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M: Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol; 2009 Aug;83(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
  • In 1997-2003, a protocol for treatment of acute myeloid leukaemia (AML) (except promyelocytic leukaemia) was activated in four Swedish health care regions covering 50% of the national population.
  • Two hundred seventy-nine patients with de novo or secondary (9%) AML, median age 51 (18-60) yr, corresponding to 77% of all patients in the population, were included.
  • Induction failures accounted for 55 patients; 16 early deaths eight of whom had white blood cell (WBC) >100 at diagnosis, and 39 refractory disease.
  • Thus, complete remission (CR) rate was 80%.
  • Median survival time from diagnosis in the whole group was 27 months and 4-yr overall survival (OS) rate was 44%.
  • Non-relapse mortality was 16% for allo-SCT patients.
  • Three conclusions were: (i) these data reflect treatment results in a minimally selected population-based cohort of adult AML patients <60 yr old;.
  • (ii) a risk-adapted therapy aiming at early allogeneic SCT in patients with a high risk of relapse is hampered by induction deaths, refractory disease, and early relapses; and (iii) high WBC count at diagnosis is confirmed as a strong risk factor for early death but not for relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / therapy. Population Surveillance. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385987.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, Lakomek M, Bourquin JP, Stary J, Reinhardt D: Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol; 2010 May;149(3):399-409
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
  • Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity.
  • Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA).
  • Overall survival was similar when comparing AML-BFM trial periods (trial 93: 88 +/- 8%, 98: 85 +/- 7% and 2004: 94 +/- 8%, P((logrank)) = 0.63).
  • Seventy-five (93%) patients achieved complete remission.
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230404.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


10. Hoshino T, Matsushima T, Saitoh Y, Yamane A, Takizawa M, Irisawa H, Saitoh T, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y: Sacroiliitis as an initial manifestation of acute myelogenous leukemia. Int J Hematol; 2006 Dec;84(5):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacroiliitis as an initial manifestation of acute myelogenous leukemia.
  • We herein report a 28-year-old female patient who presented with sacroiliitis as an initial manifestation of acute myelogenous leukemia (AML).
  • Although she was initially diagnosed with myelodysplastic syndrome (MDS), blasts rapidly increased and AML developed 1 month after the diagnosis of MDS with Sacroiliitis.
  • Induction chemotherapy failed to induce a complete remission of AML, but it did effectively treat the sacroiliitis.
  • However, the sacroiliitis relapsed when the leukemia cells progressed thereafter.
  • The close relationship between the occurrence of sacroiliitis and AML suggested that autoimmune sacroiliitis was a paraneoplastic phenomenon of AML in this patient.
  • Although autoimmune disorders develop in a substantial number of MDS patients, they are rarely observed in de novo AML.
  • No previous report has described sacroiliitis as the initial manifestation of de novo AML.
  • [MeSH-major] Leukemia, Myeloid, Acute. Sacroiliac Joint. Spondylitis, Ankylosing
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Blast Crisis / diagnosis. Blast Crisis / diagnostic imaging. Blast Crisis / therapy. Bone Marrow Transplantation. Fatal Outcome. Female. Humans. Radiography. Recurrence. Transplantation, Homologous


11. Claxton DF, Ehmann C, Rybka W: Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol; 2005 Jul;130(2):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
  • Non-myeloablative conditioning has extended the use of allogeneic haematopoietic transplant to many previously ineligible patients.
  • A total of 23 patients with acute myelogenous leukaemia (AML) were treated, with a median age of 59 years (range: 28-72) at transplant.
  • Only seven patients in total were in complete remission prior to transplantation.
  • Four of 12 survivors relapsed at 83, 88, 243 and 508 d and three were in remission after chemotherapy and donor lymphocyte infusion.
  • Although follow up is short, this data suggests that non-myeloablative haematopoietic cell transplantation with sirolimus (rapamycin)-based immunosuppression may provide disease control over several years in some patients with advanced and poor prognosis AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / therapy. Sirolimus / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029454.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


12. Nagai S, Nannya Y, Takahashi T, Kurokawa M: Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia. Ann Hematol; 2010 Jul;89(7):741-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19904535.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


13. Manoharan A, Reynolds J, Matthews J, Baxter H, Di Iulio J, Leahy M, Juneja S, Australasian Leukaemia and Lymphoma Group: Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study. Drugs Aging; 2007;24(6):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.
  • OBJECTIVE: To evaluate the efficacy of a flexible low-intensity combination chemotherapy (FLICC) protocol in a multicentre, phase II study of elderly patients with acute myeloid leukaemia (AML).
  • METHOD: Twenty-five patients aged 61-78 years (median 70 years) with de novo (n = 17) or secondary (n = 8) AML (cytogenetic risk: favourable 2, intermediate 18, adverse 2, unknown 3) from eight Australian centres were enrolled.
  • RESULTS: The treatment was generally well tolerated, and 13 patients (52%) achieved a complete remission (CR).
  • One patient achieved a partial remission but died on day 28 due to pneumonia.
  • The median overall survival (OS) was 6.5 months, and the median remission duration was 7.7 months.
  • Estimated 1-year survival was 32%, but patients achieving CR had an estimated 1-year survival of 64%, whereas none in the non-CR group survived to 1 year.
  • CONCLUSION: The findings of this multicentre, phase II study validate the previously reported single-institution experience with the FLICC protocol in elderly patients with AML.
  • The clinical outcome with this protocol is comparable to those reported with more aggressive anti-leukaemia protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Onkologie. 2004 Feb;27(1):72-82 [15007253.001]
  • [Cites] Haematologica. 2004 Mar;89(3):296-302 [15020267.001]
  • [Cites] Exp Cell Res. 1996 Nov 1;228(2):292-305 [8912723.001]
  • [Cites] Am J Hematol. 1992 Nov;41(3):178-83 [1415192.001]
  • [Cites] Int J Hematol. 2002 Jun;75(5):519-27 [12095154.001]
  • [Cites] Br J Haematol. 1984 Jun;57(2):301-7 [6587903.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S17-26 [14563517.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3869-76 [12393614.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2):96-106 [16616043.001]
  • [Cites] Drugs Aging. 2002;19(8):571-81 [12207551.001]
  • [Cites] Neoplasma. 2002;49(6):405-11 [12584589.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1193-6 [9264368.001]
  • [Cites] Leuk Res. 2004 Jun;28(6):571-7 [15120933.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):272-9 [2299370.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):238-44 [10846828.001]
  • [Cites] Oncologist. 2000;5(3):224-37 [10884501.001]
  • [Cites] Am J Hematol. 1995 May;49(1):48-55 [7741138.001]
  • [Cites] Oncologist. 1996;1(4):234-239 [10387995.001]
  • [Cites] Br J Cancer. 1998;77(1):40-50 [9459144.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):422-6 [8697386.001]
  • [Cites] Leuk Res. 1994 Aug;18(8):645-7 [8065167.001]
  • [Cites] Clin Med (Lond). 2001 Jul-Aug;1(4):313-6 [11525581.001]
  • [Cites] Int J Hematol. 1998 Oct;68(3):235-43 [9846008.001]
  • [Cites] Rinsho Ketsueki. 1995 Jul;36(7):657-64 [7563593.001]
  • [Cites] Blood. 2001 Sep 1;98 (5):1312-20 [11520776.001]
  • [Cites] Am J Hematol. 1997 Jun;55(2):115-7 [9209009.001]
  • (PMID = 17571913.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


14. Kolitz JE: Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol; 2006 Sep;134(6):555-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for acute myeloid leukaemia.
  • Improvements in survival in adult acute myeloid leukaemia (AML) have yet to be gleaned from either refinements in the understanding of the pathophysiology of the disease or from the expanding pool of targeted therapies.
  • Ongoing and planned trials will assess the effects of drugs targeting biological pathways whose clinical importance may vary as a function of the unique genotype and phenotype of each case of AML.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Humans. Immunotherapy. Prognosis. Remission Induction

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848792.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 165
  •  go-up   go-down


15. Wang W, Wang XQ, Xu XP, Lin GW: Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group. J Int Med Res; 2010 Mar-Apr;38(2):432-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.
  • This study was designed to evaluate the prevalence of fms-like tyrosine kinase-3 (FLT3) gene mutations in the World Health Organization classified subtypes of acute leukaemia (AL), and their prognostic significance in terms of complete remission (CR), leukaemia-free survival (LFS) and overall survival (OS).
  • Of 468 patients, 374 (79.9%) had acute myeloid leukaemia (AML) and 83 (17.7%) had acute lymphoblastic leukaemia (ALL).
  • Among the AML patients, a FLT3 internal tandem duplication (FLT3/ITD) mutation was present in 59 cases (15.8%), whereas a FLT3/D835 mutation was detected in 15 cases (4.0%).
  • The FLT3/ITD mutation was associated with a lower CR rate compared with those with no mutations (52.3% versus 71.1%) and with a shorter median OS (9 versus 18 months) in AML patients.
  • In conclusion, the FLT3/ITD mutation occurred frequently in AML and was associated with a lower CR and shorter median OS.
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515557.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


16. Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, Gratwohl A, Ferrant A, Elmaagacli A, Schwertfeger R, Locasciulli A, Zander A, Bornhäuser M, Niederwieser D, Ruutu T, Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation: Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica; 2005 Jul;90(7):969-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).
  • Leukemia in donor cells (donor cell leukemia;.
  • However, the incidence, potential pathogenetic factors, therapeutic options and outcome of patients suffering from DCL and the leukemia risk of their donors are not well defined.
  • Fourteen cases of DCL, most with a myeloid phenotype (7 cases of acute myeloid leukemia, 3 each of acute lymphocytic leukemia and 1 case of chronic myeloid leukemia) were identified.
  • The median time between transplantation and diagnosis of DCL was 17 months (4-164).
  • Chemotherapy induced remissions in DCL and 2 of 5 patients remain alive in remission after a second transplant.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia / etiology. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996934.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


17. Anderson GA, Braaten K: Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia. Urol Oncol; 2005 Nov-Dec;23(6):419-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia.
  • Extramedullary leukemia (EML) is an uncommon clinical diagnosis in patients with acute nonlymphocytic leukemia (ANLL).
  • Prostatic EML as a first site of ANLL relapse is even more rare.
  • We describe an additional case of prostatic EML as a site of ANLL relapse.
  • An asymptomatic male in ANLL remission was found to have a normal prostate-specific antigen (PSA) and a myeloid leukemic infiltrate in a newly diagnosed prostate nodule.
  • Staging was negative for ANLL relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary


18. Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B, Fasanaro A, Mele G: High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol; 2005 Jan;128(2):234-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
  • Between 30 and 50% of patients with acute myeloid leukaemia (AML) relapse after autologous stem cell transplantation (ASCT).
  • One possibility of reducing the relapse rate could be the adoption of conditioning regimens specifically designed for AML.
  • All patients had non-M3-AML and were in first complete remission (CR).
  • Our data show that a conditioning regimen based on high-dose IDA plus busulphan results in an encouraging reduction of the relapse rate after ASCT in AML.
  • [MeSH-major] Busulfan / therapeutic use. Idarubicin / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Myeloid / surgery. Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638859.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
  •  go-up   go-down


19. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood; 2007 May 1;109(9):3658-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
  • The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison.
  • We evaluated our results and those of the previous MRC, BGMT, and EORTC studies in a meta-analysis, which revealed a significant benefit of 12% in overall survival (OS) by donor availability for all patients with AML in CR1 without a favorable cytogenetic profile.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Living Donors. Transplantation Conditioning


20. Kobayashi K, Kami M, Murashige N, Kusumi E, Kishi Y, Hamaki T, Hori A, Matsumura T, Yuji K, Masuo S, Mori S, Miyakoshi S, Tanosaki R, Mitamura T, Takaue Y, Taniguchi S, Tokyo SCT Consortium Institution: Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. Br J Haematol; 2005 Jun;129(6):795-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
  • We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens.
  • Four are alive with a median follow-up of 27.6 months (range, 16.0-28.9 months); three in remission and one in relapse.
  • Cumulative incidences of relapse-related and non-relapse-related deaths at 2 years after relapse were 37% and 32% respectively.
  • Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy-based interventions; however they carry a significant risk of non-relapse mortality.
  • [MeSH-major] HLA Antigens / analysis. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Cause of Death. Female. Graft vs Host Disease / etiology. Histocompatibility Testing. Humans. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953007.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


21. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia; 2005 Dec;19(12):2030-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
  • A total of 1111 children with acute myeloblastic leukaemia (AML) were treated in four consecutive Berlin-Frankfurt-Münster (BFM) studies from 1978 to 1998.
  • The first cooperative trial AML-BFM 78 established intensive chemotherapy with seven drugs, CNS irradiation and 2-year maintenance, achieving a long-term survival (overall survival (OS)) of 40%.
  • Induction intensification in AML-BFM 83 resulted in significant improvement of disease-free survival (DFS).
  • In AML-BFM 87, the benefit of CNS irradiation in preventing CNS/systemic relapses was demonstrated.
  • In AML-BFM 93, the introduction of idarubicin during first induction followed by intensification with HAM increased the 5-year EFS, DFS and OS to 50+/-2, 61+/-3 and 57+/-2%, respectively.
  • The AML-BFM studies performed in three European countries with >70 cooperating centres have significantly improved the outcome in AML children; nevertheless, increasing experience with these intensive treatment regimens is of fundamental importance to reduce fatal complications.
  • [MeSH-major] Antineoplastic Protocols / standards. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cranial Irradiation. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Hemorrhage / etiology. Humans. Infant. Infant, Newborn. Male. Remission Induction / methods. Risk Assessment. Secondary Prevention. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304570.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglunds M, Karlsson K, Stockelberg D, Wahlin A, Aström M, Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E, Holmberg E, Nordenskjöld K, Wiklund F, Swedish Adult Acute Leukemia Registry Group: Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia; 2006 Jan;20(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
  • Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking.
  • The remission intention (RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown.
  • The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries.
  • Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the two-year overall survival, with no censored observations (6-21%) (chi-squared for trend=11.3, P<0.001; r2=0.86, P<0.02, nonparametric).
  • Differences could not be explained by demographics, and was found in both de novo and secondary leukemias.
  • Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
  • [MeSH-major] Attitude of Health Personnel. Leukemia, Myeloid / drug therapy. Patient Selection
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Registries. Remission Induction. Survival Rate. Sweden / epidemiology. Treatment Outcome


23. Zhang J, Mi YC, Wang Y, Lin D, Li W, Sun XM, Zhou K, Bian SG, Wang JX: [Study on the clinical characteristics of adult biphenotypic acute leukaemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jan;30(1):18-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the clinical characteristics of adult biphenotypic acute leukaemia].
  • OBJECTIVE: To analyze the clinical and biological characteristics and prognosis of adult biphenotypic acute leukaemia (BAL).
  • The chemotherapy regimens were accordingly for acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) or for both ALL and AML.
  • (1) The incidence of BAL in acute leukaemias was 6.7%, with a male predominance and 52.3% of BAL patients had WBC > or = 30 x 10(9)/L and 16.9% WBC > or = 100 x 10(9)/L. (2) Percentages of coexpression of myeloid and B lymphoid antigens were 81.5%, of myeloid and T lymphoid antigens 10.8%, of myeloid, B- and T lymphoid antigens 4.6%, and of B and T lymphoid antigens 3.1%. (3) Normal and abnormal karyotypes accounted for 41.5% and 58.5%, respectively in 53 BAL patients with karyotype analysis.
  • The rate of Ph (+) or bcr-abl (+) was 32.1%. (4) 31 (56.4%) of 65 patients achieved complete remission (CR), but CR rate was only 35.3% for Ph (+) or bcr-abl (+) cases. CONCLUSION:.
  • (1) High white blood cell count and coexpression of myeloid/B lymphoid antigens are common in BAL. (2) Abnormal karyotypes and Ph (+) or bcr-abl( +) often happen. (3) The treatment outcome of BAL is poor.
  • [MeSH-major] Leukemia, Biphenotypic, Acute

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563029.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Ragusa M, Avola G, Angelica R, Barbagallo D, Guglielmino MR, Duro LR, Majorana A, Statello L, Salito L, Consoli C, Camuglia MG, Di Pietro C, Milone G, Purrello M: Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer; 2010;10:377
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
  • BACKGROUND: According to the different sensitivity of their bone marrow CD34+ cells to in vitro treatment with Etoposide or Mafosfamide, Acute Myeloid Leukaemia (AML) patients in apparent complete remission (CR) after chemotherapy induction may be classified into three groups: (i) normally responsive;.
  • METHODS: To investigate the molecular bases of the differential chemosensitivity of bone marrow hematopoietic stem cells (HSC) in CR AML patients, and the relationship between chemosensitivity, mobilizing activity and relapse rates, we analyzed their AM expression profile by performing Real Time RT-PCR of 84 AM genes in CD34+ pools from the two extreme classes of patients (i.e., chemoresistant and highly chemosensitive), and compared them with normal controls.
  • We propose that their dysregulation (either due to inborn or de novo genomic mutations selected by treatment) could cause a relapse in apparent CR AML patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis. Biomarkers, Tumor / genetics. Bone Marrow Cells / metabolism. Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Cell Movement. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Neoplasm, Residual / pathology. Oligonucleotide Array Sequence Analysis. Prospective Studies. RNA, Messenger / genetics. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1993 Jul 1;82(1):15-21 [8324219.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Dec;41(12):2372-5 [19699815.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):838-48 [16247474.001]
  • [Cites] Mayo Clin Proc. 2006 Feb;81(2):247-60 [16471082.001]
  • [Cites] Toxicol Sci. 2006 Aug;92(2):587-95 [16675512.001]
  • [Cites] CA Cancer J Clin. 1996 May-Jun;46(3):165-84 [8646546.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2048-59 [9058727.001]
  • [Cites] Leukemia. 1998 Mar;12(3):382-9 [9529133.001]
  • [Cites] Leuk Res. 1998 Jun;22(6):557-60 [9678722.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Leukoc Biol. 2004 Nov;76(5):1047-56 [15328334.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):682-6 [15861191.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4770-4 [16000573.001]
  • [Cites] Med Princ Pract. 2005;14 Suppl 1:35-48 [16103712.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):611-5 [10886211.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):21-6 [11148681.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):463-9 [11673686.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3284-94 [12032770.001]
  • [Cites] Leukemia. 2003 Jan;17(1):60-7 [12529661.001]
  • [Cites] Leukemia. 2003 Jan;17(1):68-75 [12529662.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):434-41 [12580957.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3657-61 [14666661.001]
  • [Cites] Leukemia. 2004 Jan;18(1):1-10 [14574330.001]
  • [Cites] Leukemia. 2004 Feb;18(2):358-60 [14628070.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26915-21 [15078892.001]
  • [Cites] J Clin Immunol. 2004 Sep;24(5):553-60 [15359114.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):333-42 [16920238.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Curr Pharm Des. 2006;12(34):4411-25 [17168751.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):209-17 [17224646.001]
  • [Cites] Exp Hematol. 2007 Jun;35(6):957-66 [17533050.001]
  • [Cites] Bioinformatics. 2007 Sep 15;23(18):2495-7 [17644818.001]
  • [Cites] Mol Syst Biol. 2007;3:152 [18091723.001]
  • [Cites] Bioinformatics. 2008 Jan 15;24(2):282-4 [18006545.001]
  • [Cites] Cell Biol Int. 2008 Mar;32(3):329-36 [18243739.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3923-30 [18398055.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2519-26 [18451212.001]
  • [Cites] Pharmacology. 2008;81(4):275-300 [18259091.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):74-8 [18422993.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1684-97 [18339423.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):365-77 [18692687.001]
  • [Cites] Exp Hematol. 2008 Dec;36(12):1660-72 [18838202.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] Physiology (Bethesda). 2005 Oct;20:349-56 [16174874.001]
  • (PMID = 20642818.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2914706
  •  go-up   go-down


25. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood; 2006 Jul 1;108(1):88-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
  • The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR).
  • Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subsequent CR (CR > 1) and randomly assigned to treatment with HDC/IL-2 or no treatment (control).
  • Study arms were balanced for age, sex, previous treatment, leukemic karyotypes, time from CR to inclusion, and frequency of secondary leukemia.
  • These results indicate that HDC/IL-2 treatment offers an efficacious and tolerable treatment for patients with AML in remission.
  • [MeSH-major] Histamine / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. HISTAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556892.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 820484N8I3 / Histamine
  •  go-up   go-down


26. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister TA, Fitzgibbon J: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol; 2008 Nov 20;26(33):5429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.
  • PURPOSE: To determine the clinical relevance of Wilms' tumor 1 (WT1) gene mutations in acute myeloid leukemia (AML) with normal karyotype (NK).
  • Patients with WT1 mutations had an inferior response to induction chemotherapy compared with wild-type cases (complete remission rate, 79% v 90%, odds ratio [OR] = 3.02; 95% CI, 1.17 to 7.82; P = .02), a higher rate of resistant disease (15% v 4%; OR = 9.33; 95% CI, 2.38 to 36.6; P = .001), an increased cumulative incidence of relapse (67% v 43%, hazard ratio [HR] = 3.02; 95% CI, 1.69 to 5.38; P = .0008), with a reduction in both relapse-free survival (22% v 44%; HR = 2.16; 95% CI, 1.32 to 3.55; P = .005) and overall survival (26% v 47%; HR = 1.91; 95% CI, 1.23 to 2.95; P = .007) at 5 years.
  • CONCLUSION: WT1 mutations are a negative prognostic indicator in NK AML and may be suitable for the development of targeted therapy.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Genes, Wilms Tumor. Leukemia, Myeloid, Acute / genetics. Mutation


27. Shin HJ, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH, Korean Society of Hematology, AML/MDS Working Party, Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM: Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment. Jpn J Clin Oncol; 2010 Jun;40(6):556-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
  • OBJECTIVE: The purpose of this study was to re-evaluate post-remission therapy outcomes after first remission according to years of patient enrollment in patients with core binding factor acute myeloid leukaemia.
  • METHODS: We conducted a retrospective study on 138 patients aged less than 60 years diagnosed with core binding factor acute myeloid leukaemia between 1994 and 2006, comparing allogeneic stem cell transplantation and high-dose cytarabine chemotherapy as post-remission treatment options after the first remission.
  • Especially, 3-year probabilities of disease-free survival (95.2% vs. 59.3%, P = 0.008) and overall survival (95.2% vs. 59.6%, P = 0.032) of allogeneic stem cell transplantation group were significantly better than high-dose cytarabine group in cohort after 2003 of acute myeloid leukaemia patients with t(8;21).
  • In multivariate analysis in cohort after 2003, allogeneic stem cell transplantation as post-remission therapy was associated with better disease-free survival.
  • CONCLUSIONS: Allogeneic stem cell transplantation is currently the more effective post-remission therapy than it was prior to 2003 for core binding factor acute myeloid leukaemia achieving first remission.
  • On the contrary to previous findings, allogeneic stem cell transplantation provides significantly improved outcomes than high-dose cytarabine chemotherapy in acute myeloid leukaemia with t(8;21).
  • [MeSH-major] Core Binding Factors / metabolism. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Stem Cell Transplantation. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185460.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factors; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin; HDAC protocol
  •  go-up   go-down


28. Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C: Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome. Hematol Oncol; 2010 Dec;28(4):202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
  • Acute myeloid leukaemia (AML) secondary to myelodysplastic syndrome (MDS) is characterized by poor prognosis, namely in older patients.
  • The combination of fludarabine (F) with cytarabine (ARA-C) ± G-CSF was proven as effective in patients with poor risk AML.
  • The efficacy and toxicity of a regimen including F + ARA-C as sequential continuous infusion (CI-FLA) in 64 untreated patients aged >60 years, in which AML arose after a previous MDS, was investigated.
  • Overall, 43 patients (67%) achieved complete remission (CR).
  • CI-FLA is effective in elderly patients with AML secondary to previously diagnosed MDS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / complications
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Diarrhea / chemically induced. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives


29. Del Poeta G, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, Ottone T, Del Principe MI, Buccisano F, Maurillo L, Panetta P, de Fabritiis P, Stasi R, Venditti A, Amadori S, Lo Coco F: The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. Br J Haematol; 2010 May;149(3):383-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
  • Nucleophosmin gene (NPM1) mutations characterize acute myeloid leukaemia (AML) with normal karyotype and frequently co-exist with FLT3 internal tandem duplications (ITD).
  • We evaluated bcl-2, bax, NPM1 and FLT3-ITD in 222 AML patients.
  • NPM1-mutated (mt)/FLT3-ITD negative patients showed a higher complete remission (CR) rate (90%, P = 0.0002) and a longer overall survival (OS, P = 0.00007).
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148885.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


30. Trof RJ, Beishuizen A, Wondergem MJ, Strack van Schijndel RJ: Spontaneous remission of acute myeloid leukaemia after recovery from sepsis. Neth J Med; 2007 Jul-Aug;65(7):259-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukaemia after recovery from sepsis.
  • Spontaneous remission of acute myeloid leukaemia (AML) is extremely rare and usually of short duration.
  • We report two patients with documented AML who developed spontaneous remission of their leukaemia shortly after an episode of severe sepsis and respiratory failure requiring mechanical ventilation.
  • The underlying mechanisms of spontaneous remission remain unclear but an association with preceding blood transfusions and severe systemic infections has been reported.
  • Better insights into the mechanisms of spontaneous remission of AML after recovery from sepsis could help in developing new therapies for AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Sepsis / complications
  • [MeSH-minor] Adult. Anti-Bacterial Agents / administration & dosage. Antineoplastic Agents / administration & dosage. Humans. Intensive Care Units. Iraq / ethnology. Male. Netherlands. Pulmonary Ventilation. Remission, Spontaneous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656812.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


31. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2010 Feb 20;28(6):955-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • PURPOSE To conduct a pilot study to determine the safety, feasibility, and engraftment of haploidentical natural killer (NK) cell infusions after an immunosuppressive regimen in children with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS Ten patients (0.7 to 21 years old) who had completed chemotherapy and were in first complete remission of AML were enrolled on the Pilot Study of Haploidentical Natural Killer Cell Transplantation for Acute Myeloid Leukemia (NKAML) study.
  • With a median follow-up time of 964 days (range, 569 to 1,162 days), all patients remain in remission.
  • We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy. Killer Cells, Natural / transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy


32. Adam Z, Pour L, Krejcí M, Korístek Z, Navrátil M, Krivanová A, Zahradová L, Hájek R: [Treatment of Waldenström macroglobulinaemia--the experience of one centre]. Vnitr Lek; 2009 Jan;55(1):9-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age upon diagnosis of the symptomatic form of WM and start of treatment was 59 (51-78) years.
  • Decrease in immunoglobulin concentration under the lower physiological limit is not referred to as a characteristic sign of WM, yet it was recorded in 7 out of 19 patients in our patient group and continued after chemotherapy, with the affected patients suffering from infections in remission more often than those with physiological values of immunoglobulins.
  • The first line of treatment achieved complete remission (CR) in 15% cases (3/15).
  • Partial remission (PR) was achieved by 63% of patients (12/19).
  • The first relaps of the disease was recorded in 5 patients (2 of whom had PR and 3 MR) who achieved remission after additional lines of therapy.
  • Additional malignant disease was diagnosed in 3 patients: 1 colon carcinoma, 1 acute myeloid leukaemia (AML) and 1 myelodysplastic syndrome (MDS).
  • Of the three patients only the patient with MDS has survived and is now without any evidence of the presence of WM, i.e. in complete remission at 41 months after the start of therapy.
  • It is not possible to determine the median of the first remission or the median of total survival due to the short follow up interval.
  • [MeSH-major] Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / drug therapy


33. Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M: Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin; 2005 Mar;21(3):403-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Arsenic trioxide delivers high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukaemia (APL), and is associated with high rates of molecular remission as indicated by PCR negativity for the PML-RARalpha gene.
  • Investigations of this agent are ongoing in a range of haematological malignancies, and studies in newly diagnosed APL, acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), multiple myeloma (MM) and chronic myelogenous leukaemia (CML) are reviewed here using published articles and presentations at international congresses to June 2004.
  • In AML, although results with single-agent arsenic trioxide were not encouraging, treatment using arsenic trioxide in combination with ascorbic acid is a proposed strategy in elderly patients not able to withstand intensive chemotherapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15811209.001).
  • [ISSN] 0300-7995
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 75
  •  go-up   go-down


34. Min WS, Kim HJ, Choi Y, Jeong HY, Kim CC: Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients. Hematol Oncol; 2007 Jun;25(2):76-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients.
  • To correlate clinical outcomes with the expression of interleukin-2 receptor alpha (CD25) positive cells during induction chemotherapy (IC) in adult patients with acute myeloid leukaemia (AML), we investigated the prognostic importance of subsets of peripheral blood (PB) CD45+CD25+ cells.
  • Seventy-five patients with newly diagnosed AML received the same initial IC; and serial PB samples were taken.
  • In addition, patients in complete remission (CR) (n = 61) demonstrated relatively lower levels of steady PB CD45+CD25+ after standard IC.
  • [MeSH-major] Interleukin-2 Receptor alpha Subunit / analysis. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 John Wiley & Sons, Ltd.
  • (PMID = 17200986.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


35. Le Dieu R, Taussig D, Lister TA, Gribben JG: Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. J Immunol Methods; 2009 Aug 31;348(1-2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens.
  • To date, studies on T cells in acute myeloid leukemia (AML) have been limited to flow cytometric analysis of whole peripheral blood mononuclear cell (PBMC) specimens or functional work looking at the impact of AML myeloblasts on normal or remission T cells.
  • In order specifically to study T cells in presentation AML specimens, we set out to develop a method of isolating highly pure CD4 and CD8 T cells by negative selection from the peripheral blood (PB) of newly diagnosed AML patients.
  • This technique, unlike T cell selection from PB from normal individuals or from patients with chronic lymphocytic leukaemia, was extremely problematic due to properties of the leukaemic myeloblasts.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Immunomagnetic Separation / methods. Leukemia, Myeloid, Acute / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576900.001).
  • [ISSN] 1872-7905
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501940; United States / NCI NIH HHS / CA / P01 CA081534; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / Antigens, CD11c; 0 / Antigens, CD34; 0 / Antigens, CD36; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / IL3RA protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


36. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z: Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci; 2007 Jun 29;362(1482):959-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
  • However, we can gain some insight into how this can be done by looking back over the 50-year history of taming acute promyelocytic leukaemia (APL).
  • APL is the M3 type of acute myeloid leukaemia characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding tendency and the presence of the chromosomal translocation t(15;17) or variants.
  • APL was considered the most fatal type of acute leukaemia five decades ago and the treatment of APL was a nightmare for physicians.
  • The first breakthrough came from the use of anthracyclines which improved the complete remission (CR) rate, though the 5-year overall survival could only be attained in a small proportion of patients.
  • Of note, both ATRA and ATO trigger catabolism of the PML-RARalpha fusion protein which is the key player in APL leukaemogenesis generated from t(15;17), targeting the RARalpha (retinoic acid receptor alpha) or promyelocytic leukaemia (PML) moieties, respectively.
  • Strikingly, a clearance of PML-RARalpha transcript in an earlier and more thorough manner, and a higher quality remission and survival in newly diagnosed APL are achieved when ATRA is combined with ATO, as compared to either monotherapy, making APL a curable disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2001 Jan;38(1):26-36 [11172537.001]
  • [Cites] J Exp Med. 2001 Feb 19;193(4):531-43 [11181704.001]
  • [Cites] Nat Med. 2001 Jun;7(6):680-6 [11385504.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3919-24 [11389035.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1361-71 [11413191.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7223-33 [11704850.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]
  • [Cites] Blood. 2002 Feb 1;99(3):759-67 [11806975.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1014-22 [11807007.001]
  • [Cites] Cell. 2002 Jan 25;108(2):165-70 [11832207.001]
  • [Cites] Oncologist. 2002;7 Suppl 1:1-13 [11961204.001]
  • [Cites] Blood. 2002 May 1;99(9):3136-43 [11964275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8283-8 [12060771.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1373-80 [12438428.001]
  • [Cites] Curr Drug Metab. 2003 Feb;4(1):1-10 [12570742.001]
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):117-24 [12633864.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):539-53 [12899709.001]
  • [Cites] Cell. 2003 Oct 31;115(3):305-18 [14636558.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9048-57 [14663483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):389-401 [15093545.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1163-74 [15096541.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1373-9 [15190260.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):205-11 [15356634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1970 Nov;67(3):1542-9 [5274478.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Feb;70(2):343-6 [4510279.001]
  • [Cites] Blood. 1973 Apr;41(4):489-96 [4510926.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Lancet. 1977 Mar 5;1(8010):549-50 [65649.001]
  • [Cites] Cancer. 1978 Jun;41(6):2484-90 [274995.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):259-65 [9806544.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1206-16 [12973844.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:1-13 [14633774.001]
  • [Cites] Nature. 1978 Aug 10;274(5671):535-9 [307692.001]
  • [Cites] Br J Haematol. 1978 Dec;40(4):509-17 [365215.001]
  • [Cites] Br J Haematol. 1980 Jan;44(1):169-70 [6929699.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8428-32 [7915840.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):323-36 [8570209.001]
  • [Cites] EMBO J. 1996 Jan 2;15(1):110-24 [8598193.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3624-9 [8622986.001]
  • [Cites] Leukemia. 1996 Apr;10(4):735-40 [8618456.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2826-32 [8874178.001]
  • [Cites] Blood. 1997 Jan 15;89(2):376-87 [9002938.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2551-6 [9122233.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5302-7 [9144232.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):61-70 [9427741.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2244-51 [9746761.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]
  • [Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Med Oncol. 1999 Apr;16(1):58-64 [10382944.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1062-70 [10400422.001]
  • [Cites] Hum Mol Genet. 1999 Sep;8(9):1741-9 [10441338.001]
  • [Cites] Acta Med Scand. 1957 Nov 29;159(3):189-94 [13508085.001]
  • [Cites] Schweiz Med Wochenschr. 1959 Jun 6;89:604-8 [13799642.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):143-53 [15710327.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e12 [15696202.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1541-50 [10688806.001]
  • [Cites] Cell Death Differ. 2000 May;7(5):447-60 [10800078.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40 [6930676.001]
  • [Cites] Med Pediatr Oncol. 1981;9(1):5-15 [6936607.001]
  • [Cites] Blood. 1981 Jun;57(6):1000-4 [6939451.001]
  • [Cites] Br J Haematol. 1982 Feb;50(2):201-14 [6949609.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):18-25 [3855265.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Am J Med. 1986 May;80(5):789-97 [3458366.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):7-13 [3422032.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Clin Exp Immunol. 1990 Mar;79(3):448-53 [2317949.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1704-9 [2224119.001]
  • [Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]
  • [Cites] Chin Med Sci J. 1991 Jun;6(2):65-70 [1804379.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1916-9 [1562718.001]
  • [Cites] Ann Hematol. 1992 Jun;64(6):270-2 [1637880.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]
  • [Cites] J Korean Med Sci. 1991 Dec;6(4):299-307 [1844638.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2260-7 [8387545.001]
  • [Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1350-3 [8057672.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1496-504 [10942397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8 [10954752.001]
  • [Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]
  • (PMID = 17317642.001).
  • [ISSN] 0962-8436
  • [Journal-full-title] Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • [ISO-abbreviation] Philos. Trans. R. Soc. Lond., B, Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 90
  • [Other-IDs] NLM/ PMC2435563
  •  go-up   go-down


37. Park EK, Jeon JS, Noh HJ, Won JH, Park HS: Complete remission of IgA nephropathy after bone marrow transplantation for acute myeloid leukaemia. NDT Plus; 2008 Dec;1(6):420-422
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of IgA nephropathy after bone marrow transplantation for acute myeloid leukaemia.
  • A 32-year-old woman was found to have IgA nephropathy and acute myeloid leukaemia.
  • We herein report a case of complete remission of IgA nephropathy after BMT for acute myeloid leukaemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Med. 2004 Oct;95(5):411-8 [15467516.001]
  • [Cites] Nat Med. 1998 Feb;4(2):153-5 [9461184.001]
  • [Cites] Kidney Int. 1996 Mar;49(3):839-45 [8648928.001]
  • [Cites] J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S2-6 [15938024.001]
  • [Cites] Exp Nephrol. 2002;10(1):51-8 [11803205.001]
  • [Cites] J Am Soc Nephrol. 2001 Jul;12(7):1401-9 [11423569.001]
  • [Cites] Kidney Int. 2007 Aug;72(3):319-27 [17495863.001]
  • [Cites] Clin Exp Nephrol. 2003 Sep;7(3):179-85 [14586713.001]
  • [Cites] N Engl J Med. 2002 Sep 5;347(10):738-48 [12213946.001]
  • (PMID = 28657023.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; IgA nephropathy / bone marrow transplantation
  •  go-up   go-down


38. Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, Mousset S, Hoelzer D, Martin H: High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol; 2005 Oct;84(11):748-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
  • In a pilot study high-dose melphalan (HD-Mel, 200 mg/m2) and autologous stem cell transplantation (ASCT) were administered to 14 patients (median age 52, range 29-60 years) with acute myeloid leukaemia (AML) in first relapse after a previous ASCT in first complete remission (n=11) or chemotherapy (n=3).
  • Thirteen (93%) of 14 patients achieved a second complete remission (CR2), including all four patients who had been refractory to MTC.
  • Three MTC-refractory patients, but none of the upfront HD-Mel patients, died due to an allograft-related non-relapse cause.
  • Our results highly encourage to further investigate HD-Mel and ASCT as a promising salvage regimen for relapsed AML patients for whom autologous peripheral blood stem cells are available.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Melphalan / therapeutic use. Salvage Therapy / methods. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001243.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


39. Gonen C, Celik I, Cetinkaya YS, Haznedaroglu I: Cytarabine-induced fever complicating the clinical course of leukemia. Anticancer Drugs; 2005 Jan;16(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytarabine-induced fever complicating the clinical course of leukemia.
  • The aim of this study is to assess the frequency and clinical characteristics of cytosine arabinoside-induced fever in patients with acute myeloid leukemia in remission, receiving high-dose (3 g/m2) consolidation therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cytarabine / adverse effects. Fever / chemically induced. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613905.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


40. Rajić Z, Colović N, Sretenović M, Plecić M, Janković S, Bakrac M, Colović M: [Hepatosplenic candidiasis in acute leukaemia patients]. Srp Arh Celok Lek; 2008 Jul-Aug;136(7-8):414-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatosplenic candidiasis in acute leukaemia patients].
  • INTRODUCTION: Hepatosplenic candidiasis is a disseminated invasive fungal infection that may affects patients with acute leukaemia.
  • CASE OUTLINE: The authors present three patients, two women and one men, aged 23, 26 and 33 years, with acute leukaemia; one with acute myeloblastic and two with acute lymphoblastic leukaemia who developed hepatosplenic candidiasis.
  • The diagnosis was based on prolonged fever, elevated serum bilirubin and alkaline phosphatase, as well as characteristic lesions on computed tomography, nuclear magnetic resonance and ultrasonographic findings and positive blood culture in one patient.
  • Two patients died due to progression of leukaemia.
  • CONCLUSION: If leukaemia patient in remission after chemotherapy develops a prolonged fever of unknown origin, hepatosplenic candidiasis has to be considered and all efforts should be done to diagnose it.
  • The diagnosis is based on clinical presentation and imaging techniques.
  • [MeSH-major] Candidiasis / complications. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Liver Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / complications


41. Staal-Viliare A, Latger-Cannard V, Rault JP, Didion J, Grégoire MJ, Bologna S, Witz B, Jonveaux P, Lecompte T, Rio Y: [A case of de novo acute basophilic leukaemia: diagnostic criteria and review of the literature]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):361-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of de novo acute basophilic leukaemia: diagnostic criteria and review of the literature].
  • [Transliterated title] A propos d'un cas de leucémie à basophiles de novo: critères diagnostiques et revue de la littérature.
  • We report a case of a de novo acute basophilic leukaemia, revealed by an infectious pneumopathy in a 73 year old man.
  • Immunophenotypic studies showed myeloid blasts, without maturity marker, CD 117 negative and CD203 cytoplasmic positive, the latter known to be highly representative of the basophilic lineage.
  • Thus, imatinib was added to the conventional chimiotherapy and the patient is currently in complete remission.
  • This clinical prompted allows us to review the literature on acute basophilic leukaemia and to state on the different diagnostic criteria of this rare disorder.
  • [MeSH-major] Leukemia, Basophilic, Acute / blood. Leukemia, Basophilic, Acute / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829481.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


42. Ziegler DS, Dalla Pozza L, Waters KD, Marshall GM: Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy. Med J Aust; 2005 Jan 17;182(2):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy.
  • In most cases, childhood leukaemia has a fetal origin, but multiple molecular events are required after birth for pre-leukaemic cells to progress to leukaemia.
  • Cure rates for acute lymphoblastic leukaemia (ALL) now approach 80%.
  • A high level of minimal residual disease detected by polymerase chain reaction in patients with ALL in remission has profound prognostic importance and is the focus of a major Australian study attempting to prevent relapse in these children.
  • [MeSH-major] Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / adverse effects. Child. Cranial Irradiation / adverse effects. Humans. Leukemia / diagnosis. Leukemia / physiopathology. Leukemia / therapy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15651967.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 45
  •  go-up   go-down


43. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Jul;19(7):1312-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demography at ASCT was 61% stage IV, median age 31 years (18-69), median prior treatment (tx) regimens 3 (2-7), median Hasenclever index 3 (0-6); 150 patients had responding disease [54 complete remission (CR), 96 partial remission (PR)], and 45 patients had untested relapse/refractory disease.
  • Twenty (10%) patients developed second cancer (seven secondary acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS)).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356139.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


44. Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B: Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol; 2010 Apr;89(4):365-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
  • Thirty-six percent of patients progressed into acute myeloid leukaemia.
  • However, erythroid and cytogenetic responders had a significantly decreased risk of progression to acute myeloid leukaemia (p = 0.001 and p = 0.009, respectively) compared to non-responders.
  • Three and 5 years after study entry, the cumulative incidence of acute myeloid leukaemia for patients with a cytogenetic response was 10% and 21%, respectively, and for patients without cytogenetic response, it was 46% and 60%.
  • Patients with del(5q) myelodysplastic syndromes without erythroid or cytogenetic remission after treatment with lenalidomide have a high risk for clonal evolution and acute myeloid leukaemia progression.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 5. Erythroid Cells / drug effects. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Failure


45. Craddock C, Tauro S, Moss P, Grimwade D: Biology and management of relapsed acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):18-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and management of relapsed acute myeloid leukaemia.
  • Disease relapse remains the major cause of treatment failure in adults with acute myeloid leukaemia (AML).
  • This reflects both the failure of current salvage regimens and the absence of effective strategies to secure long-term disease-free survival in those patients who achieve a second remission.
  • As a result, a range of novel drug and transplant therapies has become available in patients with relapsed AML, and it is realistic to anticipate that a co-ordinated assessment of their clinical and biological impact will provide the basis for the design of future, more effective treatments in relapsed disease.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / contraindications. Humans. Immunologic Factors / therapeutic use. Recurrence. Salvage Therapy / methods. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801952.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors
  • [Number-of-references] 156
  •  go-up   go-down


46. Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C, German Acute Myeloid Leukaemia Cooperative Group, Study Alliance Leukemia Investigators: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet; 2010 Dec 11;376(9757):2000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
  • BACKGROUND: About 50% of patients (age ≥60 years) who have acute myeloid leukaemia and are otherwise medically healthy (ie, able to undergo intensive chemotherapy) achieve a complete remission (CR) after intensive chemotherapy, but with a substantially increased risk of early death (ED) compared with younger patients.
  • METHODS: Multivariate regression analysis was used to develop risk scores with or without knowledge of the cytogenetic and molecular risk profiles for a cohort of 1406 patients (aged ≥60 years) with acute myeloid leukaemia, but otherwise medically healthy, who were treated with two courses of intensive induction chemotherapy (tioguanine, standard-dose cytarabine, and daunorubicin followed by high-dose cytarabine and mitoxantrone; or with high-dose cytarabine and mitoxantrone in the first and second induction courses) in the German Acute Myeloid Leukaemia Cooperative Group 1999 study.
  • Risk prediction was validated in an independent cohort of 801 patients (aged >60 years) with acute myeloid leukaemia who were given two courses of cytarabine and daunorubicin in the Acute Myeloid Leukaemia 1996 study.
  • FINDINGS: Body temperature, age, de-novo leukaemia versus leukaemia secondary to cytotoxic treatment or an antecedent haematological disease, haemoglobin, platelet count, fibrinogen, and serum concentration of lactate dehydrogenase were significantly associated with CR or ED.
  • INTERPRETATION: The scores for acute myeloid leukaemia can be used to predict the probability of CR and the risk of ED in older patients with acute myeloid leukaemia, but otherwise medically healthy, for whom intensive induction chemotherapy is planned.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Internet. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Germany. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Multivariate Analysis. Predictive Value of Tests. Prognosis. Regression Analysis. Remission Induction. Risk Assessment. Risk Factors. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1967-8 [21131041.001]
  • (PMID = 21131036.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  • [Investigator] Fuss H; Hennesser D; Potenberg J; Ludwig WD; Schöndube D; Späth-Schwalbe E; Hesse-Amojo S; Mayr A; Grüneisen A; Boewer C; Derwahl M; Englisch HJ; Rick O; Siegert W; Notter M; Uharek L; Thiel E; Dörken B; Arnold R; Huhn D; Knigge O; Kolloch R; Krümpelmann U; Weh AJ; Zumsprekel A; Teschendorf C; Stechstor M; Trenn G; Wörmann B; Pflüger KH; Wolff T; Hertenstein B; Thomssen H; Peyn A; Rasche H; Heidtmann HH; Marquard F; Hähnel M; Fiedler F; Herbst R; Hallek M; Staib P; Heike M; Niederste-Hollenberg A; Pielken H; Hindahl H; Röllig C; Schaich M; Thiede C; Kramer M; Ehninger G; Aul C; Giagounidis A; Lange W; Kuhlemann SE; Flasshove M; Karow J; Gramatzki M; Helm G; Fuchs R; Schlegel F; Saal JG; Serve H; Kiehl M; Höffkes HG; Arland M; Meckenstock G; Giagounidis A; Haase D; Trümper L; Griesinger F; Gropp C; Depenbusch R; Eimermacher H; Schütte W; Haak U; Fasshaür E; Schmitz N; Stuhlmann R; Braumann D; Schmidt H; Buhrmann K; Balleisen L; Schubert J; Dürk H; Burk M; Ho AD; Mahlknecht U; Lange JG; Schmitz-Hübner U; Bartholomäus A; Fauser A; Link H; Hagmann FG; Wolf M; Ritter B; Frieling T; Planker M; Köchling G; Hartmann F; Middeke H; Gründgens C; Constantin C; Schalk KP; Jost KA; Fetscher S; Schmielau J; Wagner T; Uppenkamp M; Hoffmann M; Hehlmann R; Lengfelder E; Neubauer A; Schwonzen M; Spangenberg H; Bodenstein H; Tischler J; Graeven D; Kohl D; Heuer T; Pohlmann H; Brack N; Nibler K; Fleckenstein D; Haferlach T; Haferlach C; Schnittger S; Kern W; Emmerich B; Dengler R; Schlag B; Hiddemann W; Braess J; Spiekermann K; Berdel WE; Büchner T; Kienast J; Mesters R; Müller-Tidow C; Krug U; Koschmieder S; Volpert S; Wieacker P; Sauerland MC; Heinecke A; Köpcke W; Wilhelm M; Wandt H; Schäfer-Eckart K; Hirsch F; Seeber B; Hartlapp J; Hegge T; Peceny R; Koch O; Innig G; Südhoff T; Wagner T; Maschmeyer G; Kreuser ED; Schenk M; Reichle A; Andreesen R; Huff H; Schönberger D; Geer T; Heissmeyer H; Labenz J; Gassmann W; Gaske T; Käsberger J; Aulitzky WE; Leimer L; Clemens MR; Mahlberg R; Frickhofen N; Fuhr HG; Schwerdtfeger R; Augener W; Engberding R; Winter R; Sandmann M; Einsele H; Weissinger F; Rückle-Lanz H; Brugger W; Papakonstantinou G; Kreibich U; Schott G; Sommer S; Zschille W
  •  go-up   go-down


47. Buda G, Romagnoli MC, Galimberti S, Figus M, Papineschi F, Nardi M, Petrini M: Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma. Melanoma Res; 2006 Oct;16(5):467-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma.
  • We report a rare case of a patient with bilateral uveal melanoma (the first eye surgically treated 6 years before the occurrence of melanoma in the contralateral eye), who developed an acute myeloid leukaemia.
  • [MeSH-major] Eye Neoplasms / complications. Eye Neoplasms / diagnosis. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Melanoma / complications. Melanoma / diagnosis. Neoplasms, Second Primary / diagnosis. Uveal Neoplasms / complications. Uveal Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Middle Aged. Remission Induction. Treatment Outcome


48. Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, Waterfall M, Samuel K, Yin J, Johnson P, Turner M: Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol; 2006 Apr;133(2):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia.
  • Twenty-two patients with acute myeloid leukaemia were recruited into a phase I/II clinical trial investigating the vaccination of patients in complete remission (CR) with autologous dendritic-like leukaemia cells (DLLC).
  • At trial entry, leukaemia cells were harvested and tested for their ability to undergo cytokine-induced dendritic cell differentiation.
  • Five patients achieved both CR and had leukaemia cells that successfully underwent differentiation and therefore proceeded to vaccination.
  • Increases in anti-leukaemic T-cell responses were demonstrated in four patients, but only two of the five remained in remission more than 12 months postvaccination.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Dendritic Cells / transplantation. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Feasibility Studies. Female. Humans. Hypersensitivity, Delayed. Interferon-gamma / biosynthesis. Lymphocyte Count. Male. Middle Aged. Neoplasm, Residual. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Regulatory / immunology. Treatment Outcome. Vaccination / adverse effects. Vaccination / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 Aug;134(4):445-6; author reply 446-7 [16822293.001]
  • (PMID = 16611305.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


49. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH: Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev; 2005 Nov;19(6):289-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
  • Acute lymphoblastic leukaemia (ALL) responds well to chemotherapy and the majority of children and a significant proportion of adults are cured of their disease after primary therapy.
  • The infusion of unmodified donor lymphocytes (DLI) following relapse after allogeneic transplantation has been shown to be curative in patients with chronic myeloid leukaemia (CML).
  • For example, some strategies utilise the patients dendritic cells (DC) to present tumour antigens to donor lymphocytes and convert them into CTL either by pulsing DC taken in remission with ALL cells or lysate, fusing such 'normal' DC with ALL cells or using DC cultured from the patient's ALL cells.
  • Other approaches include exploiting the expression of leukaemia-specific antigens such as the proteinase PR-3 or the zinc finger transcription factor Wilms tumour-1 protein (WT-1) to stimulate CTL responses.
  • [MeSH-major] Immunotherapy, Adoptive. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Child. Child, Preschool. Dendritic Cells / immunology. Dendritic Cells / transplantation. Female. Graft vs Leukemia Effect / immunology. Humans. Male. Neoplasm Proteins / immunology. Secondary Prevention. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / transplantation. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275419.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 89
  •  go-up   go-down


50. Bernard F, Bordigoni P, Simeoni MC, Barlogis V, Contet A, Loundou A, Thuret I, Leheup B, Chambost H, Play B, Auquier P, Michel G: Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant; 2009 Apr;43(8):637-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.
  • We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal).
  • The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / physiopathology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Body Height. Child. Female. Growth Disorders / etiology. Humans. Male. Remission Induction. Time Factors. Treatment Outcome. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011662.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, Johansen P, Kristensen JS, Nørgaard JM: Reasons for treating secondary AML as de novo AML. Eur J Haematol; 2010 Sep;85(3):217-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reasons for treating secondary AML as de novo AML.
  • In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML).
  • In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML.
  • The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%).
  • Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006).
  • In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases.
  • Interestingly, in all further analyses of CR-rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance.
  • We conclude that the presence of secondary AML does not per se convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / complications


52. Hsiao PJ, Kuo SM, Chen JH, Lin HF, Chu PL, Lin SH, Ho CL: Acute myelogenous leukemia and acute leukemic appendicitis: a case report. World J Gastroenterol; 2009 Nov 28;15(44):5624-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia and acute leukemic appendicitis: a case report.
  • Acute myelogenous leukemia (AML) can involve the gastrointestinal tract but rarely involves the appendix.
  • We report a male patient who had 1 year partial remission from AML and who presented with apparent acute appendicitis as the initial manifestation of leukemia relapse.
  • Pathological findings of the appendix revealed transmural infiltrates of myeloblasts, which indicated a diagnosis of leukemia.
  • Although leukemic cell infiltration of the appendix is uncommon, patients with leukemia relapse can present with symptoms mimicking acute appendicitis.
  • [MeSH-major] Appendicitis / complications. Appendicitis / diagnosis. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Aged. Appendectomy. Disease Progression. Granulocyte Precursor Cells / cytology. Humans. Leukemic Infiltration / diagnosis. Leukemic Infiltration / pathology. Male. Recurrence. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / pathology. Treatment Outcome


53. Hashmi KU, Khan B, Ahmed P, Raza S, Hussain I, Mahmood A, Iqbal H, Malik HS, Anwar M: FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. J Pak Med Assoc; 2005 Jun;55(6):234-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
  • OBJECTIVE: To evaluate the efficacy and toxicity profile of the combination of fludarabine, high dose cytarabine, idarubicin, and granulocyte colony stimulating factor in refractory relapsed cases of acute leukaemia, a study is being conducted at Armed Forces Bone Marrow Transplant Centre (AFBMTC) Rawalpindi since January 2003.
  • METHODS: Twelve Patients with refractory/relapsed (Ref/Rel) acute leukaemia (AL) were treated with fludarabine 30 mg/m2 and cytosine arabinoside (AraC) Arac 2 g/m2 for 5 days, idarubicin 10 mg/m2 for 3 days, and granulocyte colony stimulating factor G-CSF 5 micro g/kg from day 0 till neutrophil recovery (ANC > 1.0 x 10(9)/1).
  • RESULTS: Patients included were refractory acute lymphoblastic leukaemia (ALL) (n=2), relapsed ALL (n = 3), refractory acute myeloid leukaemia (AML) (n = 3), secondary AML (n=2) relapsed AML (n = 1) and acute undifferentiated leukaemia (AUL) (n = 1).
  • Complete remission (CR) was achieved in 8 (66.6%) patients.
  • Three (25%) patients died of post chemotherapy complications and one patient failed to achieve remission.
  • Out of 8 patients who achieved CR, 4 underwent allogeneic bone marrow transfusion (BMT), 1 is being evaluated for the same, 1 received idorubicin, AraC and etopuside (ICE) and high dose AraC, 1 did not receive further chemotherapy and 1 relapsed two months after remission.
  • CONCLUSION: In our experience, FLAG-IDA is well tolerated and effective regimen in relapsed/refractory acute leukaemias.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Child. Cytarabine / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045091.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


54. Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP: A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer; 2006 Aug 7;95(3):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
  • To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with advanced acute myeloid leukaemia were included in this sequential Bayesian phase I dose-finding trial.
  • Eleven of the 12 patients with circulating leukaemic cells had blood blast clearance, two achieved complete remission and one with blast crisis of CMML returned in chronic phase.
  • [MeSH-major] Harringtonines / administration & dosage. Harringtonines / pharmacokinetics. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Middle Aged. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1989 Feb;25(2):263-9 [2702981.001]
  • [Cites] Clin Trials. 2006;3(1):57-71 [16539090.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1989;37(1-2):69-76 [2619511.001]
  • [Cites] Cancer Res. 1990 Apr 1;50(7):2031-5 [2317793.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Biometrics. 1990 Mar;46(1):33-48 [2350571.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1185-8 [1434802.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1189-91 [1434803.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):139-51 [11355928.001]
  • [Cites] Leukemia. 2001 Apr;15(4):567-74 [11368358.001]
  • [Cites] Stat Med. 2001 Oct 15;20(19):2827-43 [11568943.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1591-605 [11745238.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):888-93 [12942553.001]
  • [Cites] Comput Methods Programs Biomed. 2003 Oct;72(2):117-25 [12941516.001]
  • [Cites] J Zhejiang Univ Sci. 2004 Feb;5(2):230-4 [14674038.001]
  • [Cites] Mol Pharmacol. 1975 Sep;11(5):511-9 [1237080.001]
  • [Cites] Eur J Biochem. 1977 Jan;72(2):323-30 [319998.001]
  • [Cites] Cancer Treat Rep. 1983 Jul-Aug;67(7-8):693-6 [6871884.001]
  • [Cites] Cancer Treat Rep. 1983 Sep;67(9):801-4 [6883357.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):841-7 [6413744.001]
  • [Cites] Cancer Treat Rep. 1984 Sep;68(9):1085-91 [6478448.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;14(3):206-10 [3995683.001]
  • [Cites] J Clin Oncol. 1985 May;3(5):617-21 [3889229.001]
  • [Cites] Invest New Drugs. 1985;3(3):279-86 [4066221.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):967-9 [3940656.001]
  • [Cites] Cancer Treat Rep. 1986 Dec;70(12):1403-7 [3791253.001]
  • [Cites] J Natl Cancer Inst. 1988 Sep 21;80(14):1095-103 [3045335.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):813-7 [2914287.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(3):145-50 [2924372.001]
  • [Cites] Bull Cancer. 1995 Dec;82(12):987-95 [8745664.001]
  • [Cites] Leukemia. 1997 May;11(5):624-8 [9180282.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2205-9 [9395035.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2723-33 [10068280.001]
  • [Cites] Cancer. 2005 May 1;103(9):1850-5 [15786422.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):609-13 [16434987.001]
  • [Cites] FEBS Lett. 1989 Nov 6;257(2):254-6 [2583270.001]
  • (PMID = 16847470.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Harringtonines; 6FG8041S5B / homoharringtonine
  • [Other-IDs] NLM/ PMC2360653
  •  go-up   go-down


55. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M: Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia; 2010 Jan;24(1):74-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.
  • Relapse in acute myeloid leukaemia (AML) is considered to result from the persistence of drug-resistant leukaemic stem and progenitor cells (LSPC) within a bone marrow 'niche' microenvironment.
  • Identifying novel agents that have the potential to target these LSPC in their niche microenvironment will aid in the characterization of candidate agents for post-remission chemotherapy.
  • In conclusion, we have shown heterogeneity in the LSPC compartment of AML patients underpinning differential in vitro sensitivity to Mylotarg.
  • [MeSH-major] Aminoglycosides / pharmacology. Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Neoplastic Stem Cells / drug effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776761.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / P-Glycoprotein; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


56. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H, Pediatric Oncology Group: Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood; 2006 Feb 15;107(4):1315-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
  • Relapse is a major obstacle in the cure of acute myeloid leukemia (AML).
  • The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS).
  • Of the 282 children randomly assigned to receive standard DAT induction, 248 (87.9%) achieved remission compared to 253 (91%) of the 278 receiving high-dose DAT (P = ns).
  • Children with HLA-identical sibling donors who achieved a complete remission received an allogeneic bone marrow transplant as consolidation.
  • Of the 418 children who achieved remission and went on to consolidation with and without CsA, the DFS was 40.6% and 33.9%, respectively (P = .24).
  • In this study, intensifying induction with high-dose DAT and the addition of CsA to consolidation chemotherapy did not prolong the durations of remission or improve overall survival for children with AML.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1867-75 [10784627.001]
  • [Cites] Blood. 2000 Jul 1;96(1):365-8 [10891476.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Curr Oncol Rep. 2000 Nov;2(6):529-38 [11122889.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):211-33 [11355932.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):95-118 [11355926.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3605-11 [11369657.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5461-7 [11454692.001]
  • [Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Leukemia. 2002 May;16(5):833-9 [11986944.001]
  • [Cites] Leukemia. 2002 May;16(5):920-7 [11986955.001]
  • [Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]
  • [Cites] Blood. 1980 Jun;55(6):960-8 [6966518.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4665-70 [1873811.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1492-7 [7916390.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Apr;9(2):363-82 [7642468.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2329-42 [7545025.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2042-8 [8609715.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4809-16 [8639853.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3010-20 [8674056.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):315-27 [9517503.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1046-56 [10419897.001]
  • [CommentIn] Blood. 2006 Jun 15;107(12):4975-6; author reply 4976-7 [16754781.001]
  • (PMID = 16254147.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90916
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / P-Glycoprotein; 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; LJ2P1SIK8Y / Mitolactol
  • [Other-IDs] NLM/ PMC1895393
  •  go-up   go-down


57. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, Van der Lelie J, Vellenga E, Gratwohl A, Verhoef GE, Verdonck LF, Löwenberg B: Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol; 2005 Jan;128(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
  • The question as to whether autologous stem cell transplantation (SCT) after consolidation chemotherapy improves the probability of survival of patients with acute myeloid leukaemia (AML) in first remission has not been settled.
  • Here, we present the results of a phase III study conducted in newly diagnosed adult AML patients aged <60 years.
  • Patients who had reached a complete remission (CR) after two courses of induction chemotherapy and who were not eligible for a human leucocyte antigen-matched sibling SCT (n = 130), were randomized after a third consolidation cycle of chemotherapy between high-dose cytotoxic treatment and autologous bone marrow transplantation or no further treatment.
  • [MeSH-major] Leukemia, Myeloid / surgery. Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Belgium. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Netherlands. Prospective Studies. Remission Induction. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Bone Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606550.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


58. Harani MS, Adil SN, Kakepoto GN, Khilji Z, Shaikh U, Khurshid M: Significance of cytogenetic abnormalities in acute myeloid leukaemia. J Pak Med Assoc; 2006 Jan;56(1):9-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of cytogenetic abnormalities in acute myeloid leukaemia.
  • OBJECTIVE: To evaluate the role of karyotype in acute myeloid leukaemia (AML) as a predictor of response to induction chemotherapy.
  • Newly diagnosed patients with denovo AML admitted to the hospital were included in the study.
  • Diagnosis of AML was based on FAB criteria, immunophenotyping and cytogenetic studies.
  • They were treated according to standard protocols (combination of anthracycline and cytarabine -3+7) and those who had acute promyelocytic leukaemia additionally received all- trans retinoic acid (ATRA).
  • Half of the (51.2%) patients out of remaining 41 achieved complete remission on bone marrow examination after receiving induction chemotherapy.
  • In favourable risk group 3/3 (100%) achieved complete remission (CR) while 15/32 (46.9%) in intermediate risk group and 3/6 (50%) in unfavourable risk group.
  • CONCLUSION: The frequency of cytogenetic abnormalities in AML and response to induction chemotherapy was low when compared with international data possibly due to the small sample size.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454127.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Gonen C, Haznedaroglu IC, Aksu S, Koca E, Göker H, Büyükaşik Y, Sayinalp N, Ozcebe O, Dündar S: Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia. Platelets; 2005 Feb;16(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia.
  • Thrombocytopenia represents a major problem in the management of acute myeloid leukaemia (AML).
  • The data regarding the alterations of endogenous thrombopoietin (TPO) regulation during the clinical course of AML are limited.
  • The aim of this study was to investigate endogenous TPO dynamics in association with platelets during the clinical course of AML.
  • We serially measured both TPO and platelets concurrently over the entire treatment period of newly diagnosed patients receiving both remission induction and consolidation chemotherapies.
  • The median concentration of TPO in AML patients at the initial diagnosis was 469.71 pg/ml and increased significantly during the aplastic period due to remission induction chemotherapy (median: 1085.33 pg/ml) but then decreased to a level (median: 45.26 pg/ml) encountered in the healthy control subjects (median: 56.90 pg/ml).
  • In conclusion, endogenous TPO levels exhibit an inverse fluctuation in relation to platelet counts during the clinical course of AML.
  • Pharmacological stimulation of thrombopoiesis in AML with novel molecules, including the recombinant thrombopoietins and the small peptide agonists, should be based on a critical administration strategy that must consider the endogenous levels of TPO.
  • TPO levels in distinct AML disease states may explain the unsuccessful recombinant TPO trials and could help to design better strategies for 'pharmacological stimulation of thrombopoiesis' in AML.
  • [MeSH-major] Leukemia, Myeloid / blood. Thrombopoietin / blood
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Agents / therapeutic use. Blood Platelets / drug effects. Case-Control Studies. Disease Management. Female. Humans. Infection / blood. Infection / etiology. Male. Middle Aged. Platelet Count. Remission Induction. Thrombocytopenia / blood. Thrombocytopenia / etiology. Thrombopoiesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763894.001).
  • [ISSN] 0953-7104
  • [Journal-full-title] Platelets
  • [ISO-abbreviation] Platelets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


60. Pui CH, Howard SC: Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol; 2008 Mar;9(3):257-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management and challenges of malignant disease in the CNS in paediatric leukaemia.
  • With 5-year event-free survival of 80% now commonplace for paediatric acute lymphoblastic leukaemia (ALL), and 50% for paediatric acute myeloid leukaemia (AML), recent efforts have focused on optimum risk-directed treatment.
  • Because cranial irradiation can cause many acute and late complications (eg, second cancers, neurocognitive deficits, endocrine disorders, and growth impairment), it has been largely replaced by intensive intrathecal treatment and systemic chemotherapy.
  • Prophylactic cranial irradiation (12-18 Gy) is given to 2-20% of patients with ALL who have an increased risk of CNS relapse (such as T-cell immunophenotype, overt CNS disease, high-risk cytogenetic features, or poor response to remission induction treatment), and for the estimated 2% of patients with AML who have overt CNS disease at diagnosis.
  • Effective retrieval treatment is needed for patients with relapsed or refractory CNS leukaemia, and intrathecal treatment with improved efficacy and reduced side-effects remains a long-term objective.
  • Perhaps the most formidable challenge is to treat children with CNS relapse after a short initial remission or cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System. Cranial Irradiation / adverse effects. Leukemia, Myeloid, Acute. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308251.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / BETA7824; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


61. Che Y, Xu YH, Zheng GH, Guo YX: [Clinical significance of HA117 expression in children with acute leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep;40(5):873-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of HA117 expression in children with acute leukemia].
  • OBJECTIVE: To explore the role of the expression of HA117 gene in bone marrow mononuclear cells (BMMNC) with acute leukemia and multidrug resistance.
  • METHODS: HA117 gene expressions in 36 children with acute leukemia and 10 children with Idiopathic thrombocytopenic purpura (ITP) were tested using semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR) technique.
  • RESULTS: The HA117 gene was expressed in 75% of children with acute leukemia.
  • There was no significant difference in HA117 gene expression between children with acute lymphoblastic leukemia (ALL, 69.57%) and children with acute myeloid leukemia (AML, 91.67%).
  • But the semi-quantitative expression of HA117/beta-actin in AML childern was significantly higher than in ALL children (q=4.5852, P<0.01).
  • The expressions of HA117 gene and HA117/beta-actin in both ALL and AML children were significantly higher than in ITP children chi2=5.05, 8.81; q=4.4612, 6.9695; P<0.05).
  • The remission patients had lower expression of HA117/beta-actin and similar expression of HA117 compared with initially diagnosed patients.
  • The remission patients had higher expression of HA117 gene and similar expression of HA117/beta-actin compared with patients with ITP.
  • The non-remission patients had higher expression of HA117/beta-actin than remission patients and ITP patients (q=3.1705, 4.4102, P<0.05), but no significant difference from initially diagnosed patients (q=0.5470, P>0.05).
  • CONCLUSION: The expression of HA117 gene is high in the BMMNC of initially diagnosed and non-remission patients with AL.
  • But the remission patients have similar semi-quantitative expression of HA117 as patients with ITP, which indicates that a quantitative testing is more important.
  • HA117 is one of the factors that may affect the clinical remission of AML.
  • The new gene HA117 may also be associated with multidrug resistance of leukemia.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Female. Humans. Infant. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Purpura, Thrombocytopenic, Idiopathic / genetics. Purpura, Thrombocytopenic, Idiopathic / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950603.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


62. Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U: Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Leuk Res; 2009 Sep;33(9):1189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
  • Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy.
  • Assessment of remission and treatment decisions are based on cytological findings.
  • We analyzed the prognostic impact of cytogenetic remission status in 118 patients with abnormal karyotype who received induction chemotherapy.
  • Eighty-three patients achieved complete remission (CR) and 20 achieved partial remission.
  • Median survival (excluding patients with AML M3) of the CCR group was 37 months, as compared to 11 months in patients with persistence of abnormal karyotype (p < 0.0001).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Remission Induction


63. El aichaoui S, Bahiri R, Benbouazza K, Bzami F, Amine B, Allali F, Hajjaj-Hassouni N: [Leukemia revealed by polyarthritis]. Rev Med Interne; 2006 Jul;27(7):555-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukemia revealed by polyarthritis].
  • INTRODUCTION: Ostéoarticular manifestation whose reveal leukaemia in 4% of the cases, regress completely with haematological remission.
  • EXEGESIS: We report two observations of leukaemia revealed by polyarthritis.
  • A 22-year-old woman has presented a polyarthritis 8 months before de diagnosis of acute leukaemia.
  • A 34 years old men, has presented one month before admission an acute polyarthritis revealing chronic myeloid leukaemia.
  • CONCLUSION: Polyarthritis may reveal an acute or chronic leukaemia.
  • Systematic blood analysis can make a difference in diagnosis of recent polyarthritis.

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750282.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


64. Risum M, Dufva IH: [Lenalidomide in the treatment of transfusion dependent myelodysplastic syndromes]. Ugeskr Laeger; 2010 Feb 8;172(6):452-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lenalidomide is the first drug to induce transfusion independence and cytogenetic remission in patients with myelodysplastic syndrome (MDS) with deletion 5q and low or intermediate risk score.
  • However, concern has arisen about the possibility of an increased risk of transformation to acute myeloid leukaemia.
  • [MeSH-minor] Humans. Leukemia, Myeloid, Acute / etiology. Prognosis. Risk Factors. Tumor Necrosis Factor-alpha / metabolism. Vascular Endothelial Growth Factor A / metabolism


65. Slavcheva V, Lukanov T, Tzvetkov N: Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia. J BUON; 2008 Oct-Dec;13(4):589-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.
  • Myeloid sarcoma is described as tumor mass consisting of myeloblasts or immature myeloid cells, involving extramedullary tissues.
  • It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).
  • We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.
  • After remission induced by conventional chemotherapy, which continued for 3 and 10 years respectively, a myeloid sarcoma was diagnosed.
  • Two years after the diagnosis of myeloid sarcoma the patient died of haemorrhagic stroke.
  • The patient with AML-M2 continued treatment with polychemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145688.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


66. Aref S, El-Sherbiny M, Azmy E, Goda T, Selim T, El-Refaie M, Twafik E: Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia. Hematology; 2008 Apr;13(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia.
  • The levels and the prognostic relevance of serum endostatin in acute myeloid leukaemia (AML) patient are not fully clear.
  • OBJECTIVE: The aim of this study was to evaluate serum levels of endostatin in acute myeloid leukemia patients before chemotherapy and after achieving complete remission and to correlate endostatin levels with patient outcome.
  • MATERIALS AND METHODS: Serum samples from 30 adult patients (22 males and eight females, median age 37, range 19-66 years) with AML had been taken before chemotherapy was administered.
  • In addition 25 out of 30 patients were reinvestigated again at complete remission (CR).
  • Endostatin serum levels were not significantly different in the pre-treatment AML patients as compared to that in normal controls (p>0.05).
  • In AML patients the baseline endostatin levels were significantly lower than at CR (p=0.001).
  • The prognostic value of serum endostatin (sE) was also evaluated by dividing AML patients into high and low sE groups using the 75 percentile sE levels of the patients group as cutoff.
  • CONCLUSION: Elevated endostatin levels at AML diagnosis is a good prognostic marker for patients' outcome.
  • [MeSH-major] Endostatins / blood. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616876.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endostatins
  •  go-up   go-down


67. Castagnola C, Lunghi M, Caberlon S, Bonfichi M, Pascutto C, Lazzarino M: Long-term outcome of ph-negative acute lymphoblastic leukaemia in adults: a single centre experience. Acta Haematol; 2005;113(4):234-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of ph-negative acute lymphoblastic leukaemia in adults: a single centre experience.
  • BACKGROUND AND OBJECTIVES: In adult acute lymphoblastic leukaemia (ALL), unlike in childhood ALL, the percentage of long-term remitters and survivors has not improved significantly over the last decades.
  • Median age was 31 years (range 13-76); 77.1% had B-lineage ALL and 22.9% T-lineage ALL; 36.1% showed associated myeloid markers.
  • RESULTS: Complete remission (CR) was achieved in 66 patients (79.5%); 20.5% of patients were resistant.
  • Initial white blood cell count </=30 x 10(9)/l, age <35 years, and time to complete remission </=40 days were the most significant prognostic factors for OS (p < 0.05).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel
  • (PMID = 15983429.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Qian SX, Li JY, Wu HX, Lu H, Qiu HX, Chen LJ, Lu RN, Xu W, Sheng RL: [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb;17(1):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
  • The objective of this study was to investigate the efficacy and toxicity of standard-dose idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukemia (AML).
  • A total of 38 AML patients were enrolled, including 30 new diagnosed patients, 8 relapsed and refractory patients.
  • The results showed that after one course of induction therapy, the overall response rate was 89.5% (34/38), and 32 out of 38 (84.2%) patients achieved complete remission (CR), including 27 of 30 (90.0%) new diagnosed AML patients, 5 (62.5%) refractory and relapsed AML patients, all 4 patients with complex cytogenetic aberrations achieved cytogenetic CR.
  • It is concluded that standard-dose of idarubicin combined with continuous infusions of cytarabine as the induction therapy is highly effective and well tolerated approach in patients with AML, this regimen provides an opportune moment for hematopoietic stem cell transplantation.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236781.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


69. Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED: Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant; 2009 Oct;15(10):1306-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
  • Autologous peripheral blood stem/progenitor cell transplantation (APBSCT) has been investigated as a potential therapeutic option to improve outcome in patients with acute myelogenous leukemia (AML).
  • However, its optimal role in treatment for adults in remission has not been clearly established.
  • We performed a retrospective analysis on 45 patients aged 21 to 73 years (median 51 years) with de novo AML who underwent APBSCT stratified by age, complete remission status, and cytogenetic risk.
  • We conclude that APBSCT is a reasonable and safe intensive consolidation for patients with AML who do not have a suitable HLA-matched donor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy


70. Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G, Torres A, López-Pedrera C: Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol; 2007 Mar;25(1):30-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
  • The Flt3 receptor tyrosine kinase is a critical mediator in the pathogenesis of acute myeloid leukaemia (AML).
  • Flt3-activating mutations have been associated with poor prognosis and decreased overall survival of AML patients, thus Flt3 constitutes an ideal target for drug treatment of such disease.
  • Unfortunately, the monotherapy with small-molecule tyrosine kinase inhibitors in clinical trials shows that remission is not permanent, presumably by resistance of Flt3 mutants to inhibitors.
  • An alternative approach for treatment is based on the cooperation between Flt3 and additional intracellular pathways for AML transformation in some patients.
  • We investigated the importance of Flt3-activating mutations for the constitutive activation of intracellular pathways in primary AML cells, and their effect on cell survival.
  • We found that the main compounds involved in the differentiation, proliferation and survival of AML (MAPK/AKT/STAT) were constitutively activated.
  • Surprisingly, contrary to previous reports, we found that inhibition of ITD/Flt3 activity did not prevent the phosphorylation of ERK, STAT5 or Akt in some primary AML cells.
  • Our results support the hypothesis that the optimal therapeutic treatment of AML may require not only the oncogenic tyrosine kinase, but also the appropriate combination of different specific inhibitors, thus providing a more effective approach to reverse leukaemogenesis.
  • Thus, we propose that each AML patient should have an individually tailored combination treatment.
  • [MeSH-minor] Acute Disease. Cell Survival. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Leukemia, Myeloid / pathology. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. STAT Transcription Factors / metabolism. Tandem Repeat Sequences. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17128418.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / STAT Transcription Factors; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


71. Kinoshita T, Yokokawa M, Yashiro N: Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings. Clin Imaging; 2006 Jul-Aug;30(4):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings.
  • A rare case of granulocytic sarcoma (GS) of the bilateral breasts after complete remission of acute myelogenous leukemia is reported.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Sarcoma, Myeloid / diagnosis. Ultrasonography
  • [MeSH-minor] Female. Humans. Middle Aged. Rare Diseases / diagnosis


72. Gianfaldoni G, Mannelli F, Baccini M, Antonioli E, Leoni F, Bosi A: Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. Br J Haematol; 2006 Jul;134(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
  • Although several parameters are useful for risk stratification of patients with acute myeloid leukaemia (AML), there are no firm criteria for predicting response to induction treatment of individual patients.
  • Daily flow cytometry (FC) analysis, carried out during induction treatment in 30 AML patients, showed that the clearance of blasts from peripheral blood (PBC) correlated closely with response, as assessed by bone marrow FC on day 14, and by morphologic analysis at haematopoietic recovery.
  • Therefore, a major treatment outcome can be predicted very early in AML patients, thus providing an opportunity for tailoring treatment modalities from the outset.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow / immunology. Cytarabine / administration & dosage. Female. Flow Cytometry. Humans. Idarubicin / administration & dosage. Leukocyte Count. Male. Middle Aged. Pilot Projects. Prognosis. Remission Induction

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803567.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


73. Sahin FI, Kizilkilic E, Bulakbasi T, Yilmaz Z, Boga C, Ozalp O, Karakus S, Ozdogu H: Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. Clin Exp Med; 2007 Sep;7(3):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients.
  • The role of cytogenetic findings in determining the diagnosis, therapy and prognosis of acute myeloid leukaemia (AML) has become more valuable by the day.
  • In this study, the results of conventional and molecular cytogenetic analyses and clinical outcomes of 66 AML patients of different subgroups aged between 16 and 82 were evaluated.
  • Chromosomal abnormalities were detected in 17 (25.7%) patients cytogenetically at the time of diagnosis, whereas molecular cytogenetic abnormalities were detected in 21 (31.8%) patients by fluorescence in situ hybridisation (FISH).
  • During clinical follow-up, 21 patients (31.8%) achieved complete remission (CR), 2 had partial remission (PR) (3.0%) and 4 patients had progressive disease (6.06%).
  • As for the normal karyotype, each patient displayed a different clinical course, which is probably due to the molecular changes in leukaemia-related genes.
  • Here we report our findings, which correlate with previous reports and conclude that cytogenetics is a crucial marker in leukaemia diagnosis and conventional and molecular cytogenetics should be performed as well as molecular genetic diagnostic methods.
  • [MeSH-major] Leukemia, Myeloid / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Cytogenetics. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):62-7 [15604893.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1855-8 [15178581.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):235-45 [16207531.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):68-75 [15604894.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Nov;115(1):32-8 [10565297.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):352-8 [12733115.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2526-31 [11895789.001]
  • (PMID = 17972052.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


74. Stevens JM, Macdougall F, Jenner M, Oakervee H, Cavenagh J, Lister AT: Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre. Br J Haematol; 2009 Apr;145(1):40-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre.
  • This study assessed the recruitment to an acute myeloid leukaemia (AML) trial (AML15) in a single centre, evaluated whether outcome was influenced by trial entry and whether the trial population could be considered representative of all AML patients by retrospective comparison of patient characteristics, trial entry and outcome for 81 consecutive patients (<60 years).
  • Thus the overall survival estimates generated from large phase III trials may indicate that the outcome for patients with AML is better than the outcome experienced in the 'real' world.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Leukemia, Myeloid, Acute / drug therapy. Patient Selection. Randomized Controlled Trials as Topic
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Male. Middle Aged. Remission Induction. Selection Bias. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210510.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Palmieri S, Ferrara F, Leoni F, Ciolli S, Pollio F, D'Amico MR, Celentano M, Viola A, Vicari L, Izzo B, Pane F: Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol Oncol; 2007 Mar;25(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
  • In this study, we analysed the prognostic relevance of foetal liver tyrosine kinase 3 (FLT3) mutations in 73 patients with acute myeloid leukaemia (AML) with normal karyotype, who survived induction and consolidation and received autologous stem cell transplantation (ASCT) after successful mobilization of peripheral blood stem cell (PBSC).
  • In conclusion, our data suggest that myeloablative chemotherapy supported by auto-PBSCT may overcome the adverse prognostic implications of FLT3 mutations in AML.
  • However, it is to consider that autografted patients are highly selected for best response to induction, consolidation and mobilization, as well as for minor non-haematologic toxicity.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / diagnosis. Mutation. Myeloablative Agonists / therapeutic use. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Karyotyping. Male. Middle Aged. Prognosis. Remission Induction. Survival Analysis. Tandem Repeat Sequences. Transplantation, Autologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036374.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


76. Marks DI, Khattry N, Cummins M, Goulden N, Green A, Harvey J, Hunt LP, Keen L, Robinson SP, Steward CG, Cornish JM: Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol; 2006 Jul;134(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploidentical stem cell transplantation for children with acute leukaemia.
  • Some children with relapsed or high-risk acute leukaemia have an improved outcome if they have an allogeneic stem cell transplant, preferably from a sibling or well-matched unrelated donor.
  • We have investigated the role of haploidentical family members as donors in 34 patients with acute leukaemia (median age 11 years, range 1-16 years).
  • Haploidentical stem cell transplantation can produce medium term disease-free survival in a proportion of children with high-risk or relapsed acute leukaemia.
  • None of the nine patients with acute myeloid leukaemia not in remission have survived.
  • [MeSH-major] Leukemia / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adolescent. Cause of Death. Child. Child, Preschool. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Haplotypes. Histocompatibility Testing / methods. Humans. Infant. Leukapheresis. Lymphocyte Count. Male. Opportunistic Infections / etiology. Recurrence. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome


77. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol; 2008 Sep;9(9):831-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
  • METHODS: Adult patients with acute leukaemia, for whom an unrelated stem-cell transplantation was indicated and no suitable unrelated human leucocyte antigen (HLA)-matched donor had been identified, were included in the study and underwent a cord-blood transplant in San Martino Hospital, Genoa, Italy.
  • Eight patients were in first complete remission, ten in second complete remission, and 14 had advanced-stage, refractory disease.
  • Secondary endpoints included the incidence of acute graft-versus-host disease, relapse, and overall survival.
  • FINDINGS: Between March 31, 2006, and Jan 25, 2008, 32 consecutive patients with acute myeloid leukaemia (n=20) or acute lymphoblastic leukaemia (n=12) underwent a cord-blood transplant (median age 36 years [range 18-66]).
  • No patient developed grade III-IV acute graft-versus-host disease.
  • 16 patients were alive and in haematological remission at a median follow-up of 13 months (range 3-23).
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


78. Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT: Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets; 2006 Feb;10(1):51-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
  • Several new therapeutic strategies are now considered for acute myelogenous leukaemia (AML), including modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs): a large group of enzymes that alters the acetylation and, thereby, the function of a wide range of nuclear and cytoplasmic proteins.
  • The only HDAC inhibitors that have been investigated in clinical studies of AML are butyrate derivatives, valproic acid and depsipeptide.
  • In the first studies, the drugs have usually been used as continuous therapy for several weeks or months, and in most studies the drugs were used alone or in combination with all-trans retinoic acid for treatment of patients with relapsed or primary resistant AML.
  • Complete haematological remission lasting for several months has been reported for a few patients (< 5% of included patients), whereas increased peripheral blood platelet counts seem more common and have been described both for patients with AML and myelodysplastic syndromes.
  • Taken together, these studies suggest that HDAC inhibition can mediate antileukaemic effects in AML, but for most patients the clinical benefit seems limited and further studies of combination therapy are required.
  • [MeSH-major] Drug Delivery Systems / methods. Hematopoiesis / drug effects. Histone Deacetylases / metabolism. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / enzymology. Lysine / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441228.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases; K3Z4F929H6 / Lysine
  • [Number-of-references] 136
  •  go-up   go-down


79. Al-Ali H, Cross M, Lange T, Freund M, Dölken G, Niederwieser D: Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia.
  • Although much progress has been made in understanding the molecular basis of acute myeloid leukaemia (AML), this has not yet led to major improvements in the overall survival of patients.
  • In particular, the treatment of elderly patients with AML remains one of the major challenges in haematology.
  • Despite increases in complete remission rates, relapse remains a major obstacle and the major determinant of overall survival.
  • Allogeneic stem cell transplantation (SCT) is the most efficient antileukaemic treatment for patients with AML, but eligibility for the treatment was confined for a long time to younger patients.
  • More than 10 years ago, SCT protocols were initiated with reduced-intensity conditioning (RIC) rather than ablative chemoradiotherapy, with the intention of inducing a graft-versus-leukaemia effect also in elderly patients and patients with concomitant diseases.
  • Randomized studies are now being initiated to define the role of SCT in the treatment of elderly patients with AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / radiotherapy. Transplantation Conditioning / methods. Whole-Body Irradiation / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Chimerism. Combined Modality Therapy. Graft Rejection. Graft vs Leukemia Effect. Humans. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561407.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C: Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol; 2009 Feb;144(3):332-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
  • Histone deacetylase inhibitors (HDIs) are emerging as valuable new agents in the treatment of acute myeloid leukaemia (AML).
  • In a trial of 20 patients treated with the HDI sodium valproate (VPA) in combination with all trans retinoic acid and theophylline, three patients responded clinically with one complete remission (CR) and two partial remissions.
  • Quantitative polymerase chain reaction confirmed overexpression of FOSB in the CR patient blasts compared to patients failing to achieve CR, and in a subset of a larger panel of AML samples.
  • Overexpression of FOSB in K562 myeloid cells significantly increased in vitro sensitivity to VPA.
  • Thus, we propose that FOSB is a novel, potential marker of VPA sensitivity in AML.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Histone Deacetylases / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Proto-Oncogene Proteins c-fos / genetics. Valproic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036090.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOSB protein, human; 0 / Proto-Oncogene Proteins c-fos; 614OI1Z5WI / Valproic Acid; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


81. Jacobs P, Wood L: Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia. Hematology; 2005 Aug;10(4):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonogenic growth patterns correlate with chemotherapy response in acute myeloid leukaemia.
  • Cytosine arabinoside and anthracycline-containing regimens induce remission in upwards of 60% of previously untreated patients with adult acute myeloid leukaemia (AML).
  • The patients all received the same drugs in a standard protocol and achievement of complete remission correlated with growth pattern.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, Myeloid, Acute / metabolism. Neoplastic Stem Cells / metabolism. Tumor Stem Cell Assay
  • [MeSH-minor] Adolescent. Adult. Cell Survival / drug effects. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Myeloid Progenitor Cells / metabolism. Myeloid Progenitor Cells / pathology. Pilot Projects. Predictive Value of Tests. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085545.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


82. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia; 2005 Dec;19(12):2130-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.
  • Between 1988 and 2002, 758 children with acute myeloid leukaemia (AML) were treated on Medical Research Council (MRC) AML 10 and AML 12.
  • MRC AML 10 tested the role of bone marrow transplantation following four blocks of intensive chemotherapy and found that while both allogeneic bone marrow transplant (allo-BMT) and autologous bone marrow transplant (A-BMT) significantly reduced the relapse risk (RR), this did not translate into a significant improvement in overall survival (OS).
  • A risk group stratification based on cytogenetics and response to the first course of chemotherapy derived from MRC AML 10 was used to deliver risk-directed therapy in MRC AML 12.
  • While the results of MRC AML 12 remain immature, there appears to be no survival advantage for a fifth course of treatment.
  • The 5 year OS, disease-free survival (DFS), event-free survival (EFS) and RR in MRC AML 12 are 66, 61, 56 and 35%, respectively; at present superior to MRC AML 10, which had a 5-year OS, DFS, EFS and RR of 58, 53, 49 and 42%, respectively.
  • MRC AML trials employ a short course of triple intrathecal chemotherapy alone for CNS-directed treatment and CNS relapse is uncommon.
  • Improvements in supportive care have contributed to improved outcomes and the number of deaths in remission fell between trials.
  • Anthracycline-related cardiotoxicity remains a concern and the current MRC AML 15 trial tests the feasibility of reducing anthracycline dosage without compromising outcome by comparing standard MRC anthracycline-based consolidation with high-dose ara-C.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Protocols / standards. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Bone Marrow Transplantation / mortality. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / prevention & control. Child. Child, Preschool. Dose-Response Relationship, Drug. Follow-Up Studies. Humans. Infant. Infant, Newborn. Injections, Spinal. Remission Induction / methods. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304572.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


83. Grant R, Keidan J: False positive Kleihauer results: an unusual cause in a postnatal patient in remission from acute myeloid leukaemia. Int J Lab Hematol; 2009 Apr;31(2):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False positive Kleihauer results: an unusual cause in a postnatal patient in remission from acute myeloid leukaemia.
  • A 34-year-old woman, in remission from acute myeloid leukaemia, had a positive postnatal Kleihauer result.
  • Hereditary persistence of foetal haemoglobin was excluded as a Kleihauer test performed in a pregnancy prior to the development of leukaemia was negative.
  • In this case, the patient was confirmed to be in a true molecular remission from leukaemia and yet appeared to have a residual clonal population of HbF erythrocytes; the significance of this finding remains unclear.
  • [MeSH-major] Fetal Hemoglobin / analysis. Hemoglobin A2 / analysis. Leukemia, Myeloid, Acute / blood. Neoplasm Regression, Spontaneous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267811.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9034-53-1 / Hemoglobin A2; 9034-63-3 / Fetal Hemoglobin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


84. Prentice HG, Sacchi S, Russell N: Future directions in haematology: beyond multiple myeloma. Acta Haematol; 2005;114 Suppl 1:27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The European Collaboration Group on Myelofibrosis with Myeloid Metaplasia reviewed patients who received at least four weeks' thalidomide treatment, in doses ranging from 50 mg/day to 400 mg/day.
  • Data on thalidomide and acute myeloblastic leukaemia (AML) are conflicting: a recently published study indicated that thalidomide does not have a role in the management of acute myeloblastic leukaemia (AML), while other studies suggest some patients may respond because of thalidomide's ability to activate natural killer cells and cytotoxic T-lymphocytes.
  • [MeSH-minor] Animals. Blood Transfusion. Clinical Trials, Phase II as Topic. Cytokines / metabolism. Disease-Free Survival. European Union. Hemoglobins / metabolism. Humans. Killer Cells, Natural / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Lymphocyte Activation / drug effects. Myelodysplastic Syndromes / metabolism. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Organ Size / drug effects. Remission Induction. Spleen / metabolism. Spleen / pathology. T-Lymphocytes / metabolism. Waldenstrom Macroglobulinemia / metabolism. Waldenstrom Macroglobulinemia / mortality. Waldenstrom Macroglobulinemia / pathology. Waldenstrom Macroglobulinemia / therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 16166770.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cytokines; 0 / Hemoglobins; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


85. Marisavljevic D, Markovic O, Zivkovic R: An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase. Med Oncol; 2009 Dec;26(4):476-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase.
  • An unusual case of acute myeloblastic leukemia (AML) with indolent clinical course and spontaneous remission in the terminal phase is described.
  • A 63-year-old male has been diagnosed to suffer from AML, subtype M2.
  • Clinical course was slowly progressive ("smoldering" AML).
  • Five years from diagnosis patient exhibited spontaneous remission of the disease, accompanied with disappearance of del(6q) clone.
  • Additional curiosity in this case is the fact that patient's older brother died of acute lymphoblastic leukemia at the age of 71 years.
  • Possible mechanisms of spontaneous remission of AML and genetic predisposition for human leukemia are discussed with a review of the literature.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Regression, Spontaneous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):375-82 [9684934.001]
  • [Cites] Eur J Haematol. 2002 Jun;68(6):376-81 [12225396.001]
  • [Cites] Br J Haematol. 1994 Jan;86(1):210-2 [8011534.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):423-5 [11529469.001]
  • [Cites] Ann Hematol. 1996 Oct;73(4):189-93 [8890708.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Feb;58(2):181-5 [1551086.001]
  • [Cites] Leuk Res. 2001 Jan;25(1):33-38 [11137558.001]
  • [Cites] Am J Hum Genet. 1996 Nov;59(5):990-8 [8900225.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2205-9 [9395035.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):557-60 [16396781.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):189-94 [15064869.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2055-61 [12357357.001]
  • [Cites] Int J Hematol. 2001 Aug;74(2):173-7 [11594518.001]
  • [Cites] J Natl Cancer Inst. 1969 Mar;42(3):517-24 [4180615.001]
  • [Cites] Eur J Haematol. 2004 Jul;73(1):62-6 [15182340.001]
  • [Cites] Int J Lab Hematol. 2007 Oct;29(5):386-9 [17824921.001]
  • [Cites] Eur J Haematol. 2004 Sep;73(3):219-22 [15287921.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):561-7 [10492080.001]
  • (PMID = 19130323.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Kell J: Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials; 2006 May;1(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed acute myeloid leukaemia.
  • Acute myeloid leukaemia (AML) is the most common form of acute leukaemia among adults with an incidence that increases with age.
  • Modern induction chemotherapy will result in complete remission in 50-90% of patients with de novo disease, but between 10 and 25% of patients will have primary refractory disease and the majority of those who gain remission will relapse within 3 years of diagnosis.
  • Treatment of relapsed leukaemia is difficult and well-controlled trials in this group of patients are uncommon.
  • This article reviews the results of published randomised trials in relapse and refractory AML.
  • Questions addressed include the role of high dose cytarabine, with or without the addition of etoposide or mitoxantrone, the use of timed sequential chemotherapy regimens, and growth factors as a means to increase leukaemia cell sensitivity and interference with drug resistance proteins.
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / prevention & control

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473961.001).
  • [ISSN] 1574-8871
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Colony-Stimulating Factors; 0 / Immunologic Factors; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 68
  •  go-up   go-down


87. Pawelec K, Matysiak M, Niewiadomska E, Rokicka-Milewska R, Kowalczyk J, Stefaniak J, Balwierz W, Załecka-Czerpko E, Chybicka A, Szmyd K, Sońta-Jakimczyk D, Bubała H, Krauze A, Wysocki M, Kurylak A, Wachowiak J, Grund G, Młynarski W, Bulas M, Krawczuk-Rybak M, Leszczyńska E, Urasiński T, Peregud-Pogorzelski J, Balcerska A, Włazłowski M: [Results of immunosupressive therapy in children with severe aplastic anaemia. Report of the Polish Paediatric Haematology Group]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1092-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: complete remission occurred in 53 patients (51.5%), partial remission in 27 (24.7%), no response was obtained in 25 children (23.8%) on day 180, of the therapy.
  • At present 70 children (66.6%) are in first remission with lasts from 12 months to 12.5 years.
  • Transformation to acute nonlymphoblastic leukaemia was observed in two of our patients.
  • 2. In our studies among the children followed up after IS therapy, there were: 1 case of periodic nocturnal haemoglobinuria (PNH), 1 case of myelodysplastic syndrome (MDS) and 2 cases of myeloid leukaemia (probability of incidence was 3.8%).
  • [MeSH-minor] Adolescent. Antilymphocyte Serum / therapeutic use. Child. Child, Preschool. Cyclosporine / therapeutic use. Female. Follow-Up Studies. Humans. Male. Prednisolone / therapeutic use. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531832.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


88. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, Van Lint MT, Gobbi M, Miglino M, Clavio M, Risso M, Frassoni F, Bacigalupo A: Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant; 2007 Aug;40(4):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant.
  • We assessed the outcome of 170 patients with AML in first complete remission, aged 1-47 years (median 29), who had undergone an allogeneic BMT before or after 1990 (n=80 and n=90, respectively); all patients were prepared with cyclophosphamide and TBI; the median follow-up for surviving patients was 13 years.
  • Patients transplanted after 1990 were older, had a shorter interval diagnosis-BMT, had less FAB-M3 cases, received a higher dose of TBI, a higher marrow cell dose and combined (cyclosporine+methotrexate) GVHD prophylaxis.
  • In conclusion, the overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two decades, despite older age and fewer M3 cases.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Graft vs Host Disease / prevention & control. Graft vs Host Disease / therapy. Humans. Infant. Italy / epidemiology. Male. Neoplasm Recurrence, Local / therapy. Remission Induction / methods. Risk. Survival Analysis. Transplantation, Homologous


89. Bacchetta J, Douvillez B, Warin L, Girard S, Pagès MP, Rebaud P, Bertrand Y: [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia]. Arch Pediatr; 2008 Aug;15(8):1315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia].
  • Blueberry Muffin baby is a rare neonatal skin disorder.
  • We report on a newborn presenting with Blueberry Muffin syndrome and an adrenal mass which lead to the diagnosis of neuroblastoma.
  • Actually, it corresponded to an acute monoblastic leukaemia with an adrenal localization and a cerebrospinal fluid involvement.
  • Leukaemia should always be considered in such patients, even in the absence of blasts on white blood cells count and bone marrow examination, as in this patient.
  • This observation was also unusual due to spontaneous remission.
  • The patient is in complete remission at 1 year follow-up.
  • [MeSH-major] Leukemia, Myeloid, Acute. Skin Diseases / congenital
  • [MeSH-minor] Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Remission, Spontaneous. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595669.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


90. Grigg AP, Reynolds J, McQuillan A, Juneja SK, Di Iulio J, Hui C, Smith C, Kimber R, Bradstock KF, Australasian Leukaemia and Lymphoma Group: Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leuk Lymphoma; 2005 Mar;46(3):367-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
  • Forty-three fit elderly patients with de novo acute myeloid leukemia (AML) received chemotherapy with mitoxantrone and intermediate dose cytarabine (MIDAC) in a phase II clinical trial conducted by the Australasian Leukaemia and Lymphoma Group.
  • While the chemotherapy was generally well tolerated, less than half the patients achieved complete remission (CR) after induction and many of those in CR could not receive planned consolidation cycles.
  • These results suggest that only selected elderly patients with AML are likely to benefit from aggressive chemotherapy and that novel therapies are required to improve the poor prognosis of this group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Patient Selection. Pilot Projects. Prognosis. Remission Induction. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621826.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


91. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister TA, Goldstone AH, EBMT Lymphoma Working Party: Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia; 2007 Nov;21(11):2324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On multivariate analysis, younger age (P=0.003) and HDT in first complete remission (CR1) (P<0.001) correlated with longer PFS.
  • Thirty-nine patients developed secondary myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), in 34 cases having received TBI as the conditioning regimen.
  • The 5-year non-relapse mortality (NRM) was 9%.
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Registries. Remission Induction. Stem Cells / cytology. Transplantation, Autologous. Treatment Outcome


92. Saikia TK, Bakshi A, Bhagwat R, Tawde S, Nair R, Nair CN, Parikh PM: Outcome of acute myeloid leukaemia in adults: a retrospective analysis. Natl Med J India; 2005 Jan-Feb;18(1):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
  • BACKGROUND: There are little data from India on the management of acute myeloid leukaemia.
  • With better understanding of the biology of the disease, and routine use of high-dose cytarabine as post-remission therapy with or without haematopoietic blood stem cell transplantation (HSCT), the results have improved in the past two decades.
  • METHODS: A total of 166 newly diagnosed patients with AML (excluding acute promyelocytic leukaemia), 15-60 years of age were treated with daunorubicin (60 mg/m2/day x3 days) or idarubicin (12 mg/m2/day x3 days) with cytarabine (100 mg/m2/day continuous i.v. infusion x7 days) induction chemotherapy.
  • Post-remission therapy included 2 cycles of high-dose cytarabine (15-18 g/m2) followed by monthly cycles of outpatient maintenance chemotherapy x4 cycles, consisting of daunorubicin (45 mg/m2 i.v. x1 day and cytarabine 100 mg/ m2 s.c. twice daily x5 days).
  • Six patients in remission received sibling donor allogeneic HSCT.
  • RESULTS: Morphological complete remission was achieved in 69.9% of the patients.
  • The median duration of remission was 12 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Idarubicin / administration & dosage. India. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835484.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


93. Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T: Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer; 2006 Feb 15;106(4):839-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
  • BACKGROUND: Different diagnostic methods add information to define complete remission (CR) in patients with acute myeloid leukemia (AML).
  • METHODS: The authors studied 216 patients with AML at the time of initial diagnosis and during follow-up and correlated cytomorphology, interphase fluorescence in situ hybridization (FISH), and flow cytometry results to evaluate response status.
  • RESULTS: Interphase FISH was found to be correlated significantly with the clinical course at the time of complete cytomorphologic remission and was more reliable than morphology for defining CR.
  • CONCLUSIONS: The current results indicated that interphase FISH may be used as a valid MRD parameter in patients with AML.
  • Multiparameter immunophenotyping for MRD also was correlated strongly with the clinical course, and the authors suggest integrating such immunophenotyping into the routine diagnostic panel at the time of diagnosis and during the clinical course in patients with AML.
  • [MeSH-major] In Situ Hybridization, Fluorescence. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Humans. Immunophenotyping. Interphase. Male. Middle Aged. Neoplasm, Residual. Prognosis. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16419072.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


94. Rowe JM: Optimal management of adults with ALL. Br J Haematol; 2009 Feb;144(4):468-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cure rate of acute lymphoblastic leukaemia (ALL) in adults remains unsatisfactory.
  • Over 80% of adults can achieve a complete remission; however, the majority of such patients relapse.
  • Prognostic factors have been more clearly defined, moving cytogenetics and molecular determinants forefront, much like acute myeloid leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Humans. Neoplasm, Residual. Prognosis. Remission Induction. Survival Analysis. Treatment Outcome. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055668.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


95. Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E: Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol; 2010 Aug;150(3):293-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
  • This prospective Phase II study is the first to assess the feasibility and efficacy of maintenance 5-azacytidine for older patients with high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia and MDS-acute myeloid leukaemia syndromes in complete remission (CR) after induction chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. DNA Methylation. DNA, Neoplasm / metabolism. Drug Administration Schedule. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Polymerase Chain Reaction / methods. Promoter Regions, Genetic. Remission Induction. Thrombocytopenia / chemically induced. Treatment Outcome


96. Kristensen IB, Møller H, Kjaerskov MW, Yderstraede K, Møller MB, Bergmann OJ: Myeloid sarcoma developing in pre-existing pyoderma gangrenosum. Acta Derm Venereol; 2009;89(2):175-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma developing in pre-existing pyoderma gangrenosum.
  • We report here a case of pyoderma gangrenosum in a patient with myelodysplastic syndrome developing into myeloid sarcoma as a sign of transformation to acute leukaemia.
  • The patient was treated successfully with intensive chemotherapy and achieved complete remission, and her otherwise expanding ulcers started to heal.
  • This is the first reported case of secondary blastic infiltration in pyoderma gangrenosum, and it underlines the importance of performing re-biopsy of non-healing ulcers, especially in patients with an underlying haematological disease.
  • [MeSH-major] Myelodysplastic Syndromes / complications. Pyoderma Gangrenosum / complications. Sarcoma, Myeloid / complications. Skin Neoplasms / complications
  • [MeSH-minor] Cell Transformation, Neoplastic. Female. Humans. Leg Ulcer / etiology. Leg Ulcer / pathology. Leukemia, Myeloid, Acute / complications. Middle Aged


97. Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M: Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol; 2005 Oct;131(2):172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
  • Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML).
  • This phase III trial compared the efficacy and toxicity of FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly diagnosed AML patients <60 years.
  • Fifty-seven patients received FLAI, as the first induction-remission course, and 55 patients received ICE.
  • After HDAC, patients in complete remission (CR) received a second consolidation course (mitoxantrone, etoposide, Ara-C) and autologous stem cell transplantation (auto-SCT) or allogeneic (allo)-SCT, according to the age, disease risk and donor availability.
  • Both haematological (P = 0.002) and non-haematological (P = 0.0001) toxicities, especially gastrointestinal (i.e. nausea, vomiting, mucositis and diarrhoea), were significantly lower in FLAI arm.
  • Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Karyotyping. Leukocyte Count. Male. Middle Aged. Prospective Studies. Remission Induction. Stem Cell Transplantation. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 Mar;132(6):794-5; author reply 795 [16487183.001]
  • [ErratumIn] Br J Haematol. 2006 Mar;132(6):804
  • (PMID = 16197446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


98. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • Haematological remission was obtained on day 33 of induction treatment (on time).
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Child, Preschool. Daunorubicin / therapeutic use. Disease Progression. Fatal Outcome. Female. Humans. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


99. van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM: Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications. Handb Exp Pharmacol; 2009;(188):319-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
  • Immunotherapy for leukaemia patients, aiming at the generation of anti-leukaemic T cell responses, could provide a new therapeutic approach to eliminate minimal residual disease (MRD) cells in acute myeloid leukaemia (AML).
  • Alternatively, monocyte derived DC obtained at time of complete remission loaded with leukaemia-specific antigens can be used as vaccine.
  • Several sources of leukaemia-associated antigen and different methods of loading antigen onto DC have been used in an attempt to optimize antitumour responses including apoptotic cells, necrotic cell lysates and tumour-associated pep-tides.
  • Currently, the AML-derived cell line MUTZ-3, an immortalized equivalent of CD34(+) DC precursor cells, is under investigation for vaccination purposes.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Cancer Vaccines. Dendritic Cells / transplantation. Immunotherapy, Adoptive. Leukemia, Myeloid / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031033.001).
  • [ISSN] 0171-2004
  • [Journal-full-title] Handbook of experimental pharmacology
  • [ISO-abbreviation] Handb Exp Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Histocompatibility Antigens
  • [Number-of-references] 186
  •  go-up   go-down


100. Webb DK: Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol; 2005 Oct;131(1):3-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing therapy for myeloid disorders of Down syndrome.
  • Children with Down syndrome (DS) are at increased risk of leukaemia.
  • Myeloid disorders include transient abnormal myelopoiesis (TAM), myelodysplasia (MDS) and acute myeloid leukaemia (AML).
  • Mutations in the GATA-1 gene, which encodes for a transcription factor central to the normal development of the erythroid and megakaryocytic lineages, are found in cases of TAM, MDS and AML in DS children.
  • DS children with MDS/AML mostly present between the ages of 1 and 4 years, and have a large predominance of megakaryoblastic disease (French-American-British type M7).
  • The MDS and AML are part of a single disease entity (myeloid leukaemia of Down syndrome) that is extremely sensitive to chemotherapy.
  • Resistant disease and relapse are rare, but treatment-related toxicity is high, and deaths in remission have exceeded those due to disease in most series.
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / therapy. Leukemia, Myeloid / complications. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Drug Administration Schedule. Humans. Infant. Megakaryocytes / immunology. Neural Tube Defects / complications. Neural Tube Defects / therapy






Advertisement